To all users of this publication:
The information contained herein has been carefully compiled and is believed to be accurate at date of publication.

For further information on the Advanced Life Support Patient Care Standards, please contact:

Ministry of Health and Long-Term Care
Emergency Health Services Branch
5700 Yonge Street, 6th Floor
Toronto ON M2M 4K5
Phone 416-327-7900
Fax 416-327-7911

© Queen’s Printer for Ontario, 2016
TABLE OF CONTENTS

Introduction
Acknowledgements .............................................................................................................. 1
Level of Paramedics ........................................................................................................... 2
Purpose of Standards ......................................................................................................... 2
Summary ............................................................................................................................. 2
Format of the Advanced Life Support Patient Care Standards ............................................ 3
Use of the Medical Directives by Paramedics ................................................................. 3
Regional Base Hospital Compliance with CPSO Policy .................................................... 3
General Structure of a Medical Directive .......................................................................... 4
ALS Patient Care Standards Paramedic Skill Set ............................................................... 4
Consent to Treatment and Capacity Assessment ............................................................. 5
Refusal of Treatment ......................................................................................................... 6
Comprehensive Care .......................................................................................................... 7
Intravenous Access and Therapy by Primary Care Paramedics ......................................... 7
Home Medical Technology and Novel Medications ......................................................... 8
Patching ............................................................................................................................. 9
Incident Reporting ............................................................................................................ 9
Controlled Substances ..................................................................................................... 10
Responsibility of Care ...................................................................................................... 10
Research .......................................................................................................................... 11
Conventions ...................................................................................................................... 11
List of Abbreviations ...................................................................................................... 14
Reference and Educational Notes .................................................................................... 17

Table of Appendices ......................................................................................................... 18
Appendix 1 – Primary Care Paramedic Core Medical Directives
Appendix 2 – Advanced Care Paramedic Core Medical Directives
Appendix 3 – Primary Care Paramedic Auxiliary Medical Directives
Appendix 4 – Advanced Care Paramedic Auxiliary Medical Directives
Appendix 5 – Chemical Exposure Medical Directives
Appendix 6 – Certification Standard
ADVANCED LIFE SUPPORT PATIENT CARE STANDARDS

ACKNOWLEDGEMENTS

The development of this edition of the Advanced Life Support Patient Care Standards is the result of a collaborative effort of a number of stakeholders including:

Association of Paramedic Chiefs (OAPC)
Ontario Base Hospital Group (OBHG)
Ministry of Health and Long Term Care – Emergency Health Services Branch (MOHLTC EHSB)
EHSB Medical Advisory Committee (MAC)

In particular, the Ministry would like to gratefully acknowledge the following members of the MAC and Regional Base Hospitals (RBH) who provided the medical input into these standards:

Dr. Michael Lewell, Chair
Dr. Andrew Affleck
Mr. Chris Day, Primary Care Paramedic Rep.
Mr. Kyle Grant, Advanced Care Paramedic Rep.
Ms. Mary Osinga, College Rep.
Dr. Rudy Vandersluis
Dr. Michelle Welsford

Dr. Jason Prpic, Past Chair
Mr. Andy Benson, Chair, Education Subcommittee
Dr. Richard Dionne
Dr. Derek Garniss
Dr. Bruce Sawadsky
Dr. Richard Verbeek
LEVELS OF PARAMEDICS

In Ontario, there are three occupational levels of paramedics: Primary Care Paramedic (PCP), Advanced Care Paramedic (ACP), and Critical Care Paramedic (CCP). A level of paramedic is specified in Ontario Regulation 257/00 made under the Ambulance Act, RSO 1990, c A-19. Schedules 1, 2 and 3 to this regulation specify the mandatory controlled acts for each level of paramedic.

A paramedic may be authorized by a Medical Director of a RBH to perform controlled acts from the Schedule immediately above their prime occupational level. In this circumstance, the paramedic will perform the skill to the specific standard set for the skill. This general concept also applies to the performance of all advanced medical procedures that are not listed as controlled acts in Schedules 1, 2 and 3, but which are also specified in these standards.

PURPOSE OF STANDARDS

The purpose of the Advanced Life Support Patient Care Standards (ALS PCS) is to guide the specifics of patient care that are to be undertaken consistent with the scope of practice of the three occupational levels of paramedics.

The ALS PCS:
- Reflects current practices for paramedics in Ontario and provides benchmarks for paramedic performance.
- Communicates the standards of practice and care by paramedics in Ontario to paramedics, patients, other disciplines and the public in general.
- Delineates paramedic professional responsibilities and accountabilities.
- Provides a basis for evaluation of patient care practice by Ontario’s paramedics.
- Recognizes that the scope of practice for each occupational level of paramedic may have incremental add-ons, with appropriate rationale and accountability.

Summary

ALS PCS for the three occupational levels of paramedics in Ontario establish the practice and patient care parameters needed to provide high quality patient care in the varied settings throughout the province. The standards are designed to be dynamic, in order to allow for changes based upon new medical evidence and/or standards of medical practice.
FORMAT OF THE ADVANCED LIFE SUPPORT PATIENT CARE STANDARDS

This document is comprised of an Introduction section and six (6) appendices: Appendix 1 – PCP Core Medical Directives; Appendix 2 – ACP Core Medical Directives; Appendix 3 – PCP Auxiliary Medical Directives; Appendix 4 – ACP Auxiliary Medical Directives; Appendix 5 – Chemical Exposure Medical Directives; and Appendix 6 – Certification Standard. Critical Care Paramedics and Advanced/Primary Care Flight Paramedics will perform controlled acts in accordance with the Base Hospital Medical Directives issued by the Ornge Base Hospital Physician.

USE OF THE MEDICAL DIRECTIVES BY PARAMEDICS

These Medical Directives apply to paramedics who provide patient care under the license and/or authority of the RBH Medical Director. Delegation of controlled acts or Medical Directives in the ALS PCS to paramedics falls under the exclusive oversight of the MOHLTC’s RBH Programs.

The Medical Directives are designed to guide a paramedic in the provision of timely and appropriate care to ill and injured patients in the prehospital setting, in accordance with the paramedics’ training and authorized skill set. While great care has been taken in developing these Medical Directives, they cannot account for every clinical situation. Thus, they are not a substitute for sound clinical judgment.

REGIONAL BASE HOSPITAL COMPLIANCE WITH CPSO POLICY

As licensed physicians in the Province of Ontario, the RBH Medical Directors must comply with the policies of the College of Physicians and Surgeons of Ontario (CPSO). The Delegation of Controlled Acts CPSO policy, as may be amended from time to time, provides direction to Ontario physicians on the delegation of controlled acts, regardless of practice setting or type. RBHs will also follow a parallel process for delegation of other advanced medical procedures included in these Standards.
GENERAL STRUCTURE OF A MEDICAL DIRECTIVE

All Medical Directives follow the same format and are comprised of the following sections:

- **Indication:** The general medical complaint or problem to which the medical directive applies.
- **Conditions:** Clinical parameters that must be present for a procedure to be performed or for a drug to be administered.
- **Contraindications:** Clinical parameters that if present, preclude the performance of a procedure or the administration of a drug.
- **Treatment:** Description of the type of procedure to be performed or the dosing of a drug.
- **Clinical Considerations:** Key clinical points that provide general guidance to the proper performance of a procedure or the administration of a drug.

All of these sections must be taken into account before and during the implementation of a Medical Directive.

ALS PATIENT CARE STANDARDS PARAMEDIC SKILL SET

The mandatory skill set for each level of paramedic is derived from the controlled acts outlined in Schedules 1, 2, and 3 (as referenced above) and is implemented through the PCP and ACP Medical Directives. A paramedic must meet all applicable requirements set out in Regulation 257/00 to receive delegation from a RBH Medical Director.

Additional (“Auxiliary”) skills may be delegated though use of the Auxiliary Medical Directives. Delegation of Auxiliary Medical Directives by a RBH Medical Director to paramedics is optional and may be introduced after consultation and mutual agreement between the RBH and the certified ambulance service operator that employs the paramedic. Some PCP and ACP Medical Directives contain the phrase, “(if available)”. This phrase qualifies the skill or procedure as optional (i.e. auxiliary) even if included in PCP or ACP Medical Directives.
CONSENT TO TREATMENT & CAPACITY ASSESSMENT

Except in emergency circumstances described below, paramedics must obtain the patient’s consent prior to initiating treatment. Consent may be informed or implied. Informed consent may be either verbal or written. Implied consent may be assumed where a person provides a physical indication that they consent to the treatment. For example, a patient who cannot speak but extends his hand to a paramedic after the paramedic indicates she is going to perform a simple procedure, such as a blood glucose determination may be giving implied consent to the procedure.

The elements required for consent to treatment are:

- consent must be given by a person who is capable of giving consent with respect to treatment,
- consent must relate to the treatment,
- consent must be informed,
- consent must be given voluntarily, and
- consent must not be obtained through misrepresentation or fraud.

Consent to treatment is informed if, before it is given to the person, he or she has:

- received the following information that a reasonable person in the same circumstances would require in order to make a decision about the treatment:
  - the nature of the treatment,
  - the expected benefits of the treatment,
  - the material risks of the treatment,
  - the material side effects of the treatment,
  - alternative courses of action,
  - the likely consequences of not having the treatment; and
- received responses to his or her requests for additional information about those matters.

The paramedic who proposes a treatment to a person shall ensure that consent is obtained. Valid consent requires that a person has the capacity to provide consent. A person is presumed to have the capacity to provide consent with respect to treatment and a paramedic may rely on that presumption. However, a capacity assessment may be required if it is not reasonable in the circumstances to presume the person is capable of consenting to the treatment.
A patient is capable with respect to treatment if the patient is:

- Able to understand the information that is relevant to making a decision about the treatment or alternatives being proposed; and
- Able to appreciate the reasonably foreseeable consequences of a decision or lack of decision with respect to treatment.

If a paramedic is aware or is made aware that the person has a prior capable wish with respect to treatment, they must respect that wish (for example, if the person does not wish to be resuscitated).

If a person is incapable with respect to a treatment, consent may be given or refused on his or her behalf by a person who is authorized to do so under section 20 of the Health Care Consent Act, 1996.

In some instances, a person may present in an emergency situation where the person for whom the treatment is proposed is apparently experiencing severe suffering or is at risk, if the treatment is not administered promptly, of sustaining serious bodily harm.

A paramedic may administer treatment to a person without consent in an emergency situation, if there is no other authorized person available to give or refuse consent and, in the opinion of the paramedic:

- the person is not capable of giving a consent or refusal to treatment; and
- the delay required to obtain a consent or refusal on the person’s behalf will prolong the suffering that the person is apparently experiencing or will put the person at risk of sustaining serious bodily harm.

**REFUSAL OF TREATMENT**

If a patient refuses treatment, either in whole or in part, a paramedic must comply with the applicable directions contained in the Basic Life Support Patient Care Standards (BLS PCS), Section 1, Part I, Patient Refusal of Treatment and/or Transport.
COMPREHENSIVE CARE

While initiating and continuing treatment prescribed by these Medical Directives, a paramedic must ensure that the patient simultaneously receives care in accordance with the BLS PCS.

It is acknowledged that there may be circumstances and situations where complying with ALS PCS is not clinically justified, possible, or prudent (e.g. multiple crews on scene, trapped patient, extenuating circumstances, competing patient care priorities). When treatment deviates from the standards, a paramedic must document the care provided, including reasoning for deviating from the Standards.

INTRAVENTOUS (“IV”) ACCESS AND THERAPY BY PRIMARY CARE PARAMEDICS

Two levels of certification of PCPs for IV cannulation and therapy are possible.

“PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The patient must require a peripheral IV in accordance with the indications listed in the Intravenous Access and Fluid Therapy Medical Directive - Auxiliary. The ACP will perform all IV therapy in accordance with the Intravenous Access and Fluid Administration Protocol once intravenous access is obtained. PCPs certified in PCP Assist IV are not authorized to administer IV therapy.

“PCP Autonomous IV” authorizes a PCP to independently cannulate an IV according to the Intravenous Access and Fluid Therapy Medical Directive – Auxiliary. PCPs certified in PCP Autonomous IV are authorized to administer IV therapy according to applicable Medical Directives.

Certification at each level shall meet the requirements established by the provincial Medical Advisory Committee.
HOME MEDICAL TECHNOLOGY AND NOVEL MEDICATIONS

As community care advances, new home medical technologies and novel medications are being introduced for home use by highly trained patients and caregivers. They are generally used by patients with complex medical histories who may require emergent interventions which are not described in, or aligned with, the BLS PCS or ALS PCS.

A “home medical technology” is an external or internal mechanical device prescribed by a member of a regulated health profession for the purpose of treating a medical condition.

A “novel medication” is a self/caregiver-administered medication prescribed by a member of a regulated health profession that is required to treat patients with generally rare and unusually complex chronic medical conditions which are often end stage. The medication may be self/caregiver-administered by any route into any part of the body.

These can be encountered unexpectedly by paramedics without any prior knowledge that these technologies or medications are being used in the community. Paramedics may not be familiar with the use of these technologies or medications, even though they may be required to provide care.

In some cases, when Base Hospital Medical Directors are alerted to these devices, medications or care requirements, a local medical directive may be issued to guide specific care for these patients. Such directives should be followed until further consideration by the Medical Advisory Committee.

A paramedic may assume patients or caregivers have knowledge about the technology or medication if they confirm that they were trained in its use and/or administration. A paramedic should advise the patient or caregiver to follow any specific steps or provide any advice about restarting/ stopping the device or novel medication. A paramedic may only assist a patient within the authorized paramedic skill set.

When care requirements are uncertain, but the patient is stable, transport the patient. If the patient is unstable, consider patching to the Base Hospital Physician. Alternatively, consider contacting the responsible member of a regulated health profession.

A paramedic may follow written advice provided by their Base Hospital Medical Directors even if this advice is outside the conditions and contraindications of the BLS PCS and ALS PCS.
PATCHING

A paramedic should patch to the Base Hospital:

- When a medical directive contains a mandatory provincial patch point;
  **OR**
- When a RBH introduces a mandatory BH patch point;
  **OR**
- For situations that fall outside of these Medical Directives where the paramedic believes the patient may benefit from online medical direction that falls within the prescribed paramedic scope of practice;
  **OR**
- When there is uncertainty about the appropriateness of a medical directive, either in whole or in part.

In cases where a treatment option requires the prior authorization by the BHP (i.e. mandatory provincial patch point or mandatory BH patch point) AND the BHP cannot be reached despite reasonable attempts by the paramedic to establish contact, a paramedic may initiate the required treatment without the requisite online authorization if the patient is in severe distress and, in the paramedic’s opinion, the medical directive would otherwise apply. Clinical judgment must be applied and an acceptable standard of care must be met. This may be based on peer and expert review. In such cases, a paramedic should continue attempts to contact the BHP after the treatment has been initiated. All patch failures must be reported in a timely manner in accordance with local policy and procedures. Paramedics should document the attempts to patch to the BH on the Ambulance Call Report (ACR).

If a BHP directs a paramedic to perform an assessment or intervention that exceeds the paramedic’s scope of practice, the paramedic must advise the BHP of such and notify the physician that he or she cannot comply with the direction as it exceeds his or her scope of practice. In such cases, a paramedic should ask the BHP to provide alternative direction.

INCIDENT REPORTING

Paramedics shall adhere to their ambulance service policies and the Ontario Ambulance Documentation Standards (incorporated by reference in Regulation 257/00) for incident reporting. Paramedics shall also adhere to additional RBH policies regarding reporting of clinical care incidents to the RBH.
**CONTROLLED SUBSTANCES**

Where applicable, paramedics and ambulance service operators shall comply with the Canada *Controlled Drug and Substances Act*, SC 1996, c 19 and its Regulations, in accordance with the ambulance operator and RBH policy. This shall include that controlled substances (opiates and benzodiazepines) are stored in different carrying cases than other medications.

**RESPONSIBILITY FOR CARE**

While on scene, the highest level paramedic shall assess the patient and make a decision on the level of care required, and on the level of paramedic required for the care of the patient. The highest level paramedic is the ultimate patient care authority on the scene. If there is any disagreement between paramedics, the Base Hospital physician may be contacted. It is expected that when an intervention has been performed, the paramedic most appropriate for that intervention will remain responsible for the patient.

In all patient care, the highest level of paramedic is responsible for the care of the patient, including decisions on the level of care required during transport. A paramedic may choose to assign aspects of care and procedures to an alternate level paramedic, as long as the care and procedures are within that paramedic’s scope of practice. Paramedics must alert the highest level paramedic of any change of patient status.

When transferring care from one level of paramedic to another, paramedics shall provide:

- current CTAS level;
- a history of the patient’s current problem(s) and relevant past medical history;
- pertinent physical findings;
- a summary of management at scene/enroute;
- the patient’s response to treatment, including most recent vital signs;
- the reason for transfer in cases of inter-facility transfers.

The transfer of responsibility of patient care is a critical juncture along the clinical care continuum. When transferring patient care to another health care provider (e.g. nurse, physician, etc.), a paramedic must comply with the BLS PCS regarding such transfers.
RESEARCH

Clinical research is fundamental to the practice of medicine and the development of safer, more effective treatment options for patients. At times, research protocols require temporary changes to patient care standards. In recognition of the importance of prehospital clinical research, RBH Medical Directors may delegate changes in patient care standards to paramedics if the research-related treatment is endorsed by MAC–OBHG and the certified ambulance operator that employs the paramedics, approved by MOHLTC, and is supported by an appropriate research ethics review board. Changes to patient care standards will be introduced as an auxiliary medical directive. Upon completion of a prehospital clinical trial, research-related treatment must be halted and care as prescribed by BLS PCS and ALS PCS must resume.

CONVENTIONS

“Conventions” refers to a consistent application of terms throughout the Medical Directives based on definitions below.

The word ‘consider’ is used repeatedly throughout the Medical Directives. Where this word appears, it indicates that a paramedic should initiate the treatment unless there is strong clinical rationale to withhold it. A paramedic must document his or her justification for withholding treatment on the ACR.

MEDICATION DOSES AND ADMINISTRATION

Medication doses may be either in per kilogram or fixed doses, depending on common clinical practice. The number of recommended medication doses may be administered regardless of any previous self-administration by a patient. When more than one route of medication administration is listed, the order of preference for route of administration is from left to right. Clinical circumstances for each case should determine the final route chosen.

Pediatric medication doses can vary slightly according to the source of expert opinion. The pediatric medication doses in the ALS PCS are the preferred doses. However, medication doses as determined by an up-to-date version of a widely accepted pediatric emergency tape (e.g. Broselow Tape) are an acceptable alternative. Use of a pediatric emergency tape shall be documented on the ACR when it is used to determine a pediatric medication dose.
AGE AND VITAL SIGNS

The general age cut off between adults and pediatrics is 18 years. There is a wide range of “normal” for vital signs in adults and especially pediatrics. As much as possible, ages for pediatrics and cut off points for vital signs have been kept consistent throughout the Medical Directives. However, clinical research and expert opinion have resulted in a number of exceptions which in each case has been deliberately chosen and is clearly noted in each Medical Directive. There is a deliberate gap in the definition of normotension and hypotension in adults.

**ADULTS**

**Normotension** - SBP $\geq 100$ mmHg

**Hypotension** - SBP <90 mmHg

**Heart rate**: Heart rate is always in beats per minute according to a cardiac monitor when it is applied. In situations where a cardiac monitor is not indicated then the heart rate is equal to the pulse rate.

**Bradycardia** - <50 BPM

**Tachycardia** - $\geq 100$ BPM

**Tachypnea** - RR $\geq 28$ breath/min

**PEDIATRICS**

<table>
<thead>
<tr>
<th>Age</th>
<th>Respiratory Rate</th>
<th>Heart Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3 months</td>
<td>30-60</td>
<td>90-180</td>
</tr>
<tr>
<td>3-6 months</td>
<td>30-60</td>
<td>80-160</td>
</tr>
<tr>
<td>6-12 months</td>
<td>25-45</td>
<td>80-140</td>
</tr>
<tr>
<td>1-3 yr</td>
<td>20-30</td>
<td>75-130</td>
</tr>
<tr>
<td>6 yr</td>
<td>16-24</td>
<td>70-110</td>
</tr>
<tr>
<td>10 yr</td>
<td>14-20</td>
<td>60-90</td>
</tr>
</tbody>
</table>

**Normotension** – SBP $\geq 90$ mmHg + (2 x age in years)

**Hypotension** - SBP < 70 mmHg + (2 x age in years)

**Weight (kg) = (age x 2) + 10**

**HYPOGLYCEMIA:**

Age $\geq 2$ years: glucometry <4.0 mmol/L

Age <2 years: glucometry <3.0 mmol/L
LOA (Level of Awareness):

The word ‘altered’ refers to a GCS that is less than normal for the patient.

The word ‘unaltered’ refers to a GCS that is normal for the patient. This may be a GCS <15.
LIST OF ABBREVIATIONS

The following abbreviations, in alphabetical order, appear in the Advanced Life Support Patient Care Standards:

A
ACP Advanced Care Paramedic
ALS Advanced Life Support
ALS PCS Advanced Life Support Patient Care Standards
ASA acetylsalicylic acid
AV atrioventricular

B
BH Base Hospital
BHP Base Hospital Physician
BLS Basic Life Support
BP blood pressure
BPM beats per minute
BVM bag-valve-mask

C
CCP Critical Care Paramedic
COPD chronic obstructive pulmonary disease
cm centimeter
CPAP continuous positive airway pressure
CPR Cardiopulmonary Resuscitation
CPSO College of Physicians and Surgeons of Ontario
CTAS Canadian Triage and Acuity Scale
CVA cerebral vascular accident
CVAD central venous access device

D
DKA diabetic ketoacidosis

E
ECD electronic control device
ECG electrocardiogram
EDD esophageal detection device
ETCO$_2$ end tidal carbon dioxide
ETT endotracheal tube

F
FiO$_2$ fraction of inspired oxygen
FRI febrile respiratory infection
### Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>G</td>
<td>gram</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow Coma Scale</td>
</tr>
<tr>
<td>H2O</td>
<td>water</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>Hx</td>
<td>history</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IN</td>
<td>intranasal</td>
</tr>
<tr>
<td>IO</td>
<td>intraosseous</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>LOA</td>
<td>level of awareness</td>
</tr>
<tr>
<td>LOC</td>
<td>level of consciousness/loss of consciousness</td>
</tr>
<tr>
<td>MAC</td>
<td>Medical Advisory Committee</td>
</tr>
<tr>
<td>mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>MDI</td>
<td>metered dose inhaler</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>ml/kg</td>
<td>milliliter per kilogram</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters of mercury</td>
</tr>
<tr>
<td>MOHLTC</td>
<td>Ministry of Health and Long-Term Care</td>
</tr>
<tr>
<td>N/A</td>
<td>not applicable</td>
</tr>
<tr>
<td>NaCl</td>
<td>sodium chloride</td>
</tr>
<tr>
<td>nare</td>
<td>nostril</td>
</tr>
<tr>
<td>NEB</td>
<td>nebulized</td>
</tr>
<tr>
<td>NPA</td>
<td>nasopharyngeal airway</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
</tbody>
</table>
Emergency Health Services Branch, Ontario Ministry of Health and Long-Term Care

Emergency Health Services Branch, Ontario Ministry of Health and Long-Term Care

---

**O**

OBHG  Ontario Base Hospital Group
OPA  oropharyngeal airway

**P**

PCP  Primary Care Paramedic
PO  by mouth/oral
PRN  as needed

**Q**

q  every

**R**

RBH  Regional Base Hospital
ROSC  return of spontaneous circulation
RR  respiratory rate

**S**

SC  subcutaneous
SL  sublingual
SBP  systolic blood pressure
SpO₂  saturation of peripheral oxygen
STEMI  ST-segment elevation myocardial infarction

**T**

TBI  traumatic brain injury
TCA  tricyclic antidepressant
TCP  transcutaneous pacing

**U**

URTI  upper respiratory tract infection

**V**

VSA  vital signs absent

**W**

WNL  within normal limits
REFERENCE AND EDUCATIONAL NOTES

The RBHs have created a companion document of reference and educational notes intended to assist paramedics in implementing these Medical Directives. This will facilitate regular updating of these notes without having to issue frequent changes to the standards. It is expected that paramedics have mastered the relevant information as part of initial training and certification and have maintained their knowledge through continuing education and self-study. The reference and educational notes do not define a standard of care; however, they should be considered useful in ensuring that an appropriate standard of care is met.
TABLE OF APPENDICES

Appendix 1 – Primary Care Paramedic Core Medical Directives
Appendix 2 – Advanced Care Paramedic Core Medical Directives
Appendix 3 – Primary Care Paramedic Auxiliary Medical Directives
Appendix 4 – Advanced Care Paramedic Auxiliary Medical Directives
Appendix 5 – Chemical Exposure Medical Directives
Appendix 6 – Certification Standard
Appendix 1

Primary Care Paramedic
Core Medical Directives
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Medical Cardiac Arrest Medical Directive</th>
<th>1-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trauma Cardiac Arrest Medical Directive</td>
<td>1-5</td>
</tr>
<tr>
<td>Hypothermia Cardiac Arrest Medical Directive</td>
<td>1-9</td>
</tr>
<tr>
<td>Foreign Body Airway Obstruction Cardiac Arrest Medical Directive</td>
<td>1-11</td>
</tr>
<tr>
<td>Neonatal Resuscitation Medical Directive</td>
<td>1-13</td>
</tr>
<tr>
<td>Return of Spontaneous Circulation (ROSC) Medical Directive</td>
<td>1-15</td>
</tr>
<tr>
<td>Cardiac Ischemia Medical Directive</td>
<td>1-18</td>
</tr>
<tr>
<td>Acute Cardiogenic Pulmonary Edema Medical Directive</td>
<td>1-21</td>
</tr>
<tr>
<td>Cardiogenic Shock Medical Directive</td>
<td>1-23</td>
</tr>
<tr>
<td>Hypoglycemia Medical Directive</td>
<td>1-25</td>
</tr>
<tr>
<td>Bronchoconstriction Medical Directive</td>
<td>1-27</td>
</tr>
<tr>
<td>Moderate to Severe Allergic Reaction Medical Directive</td>
<td>1-30</td>
</tr>
<tr>
<td>Croup Medical Directive</td>
<td>1-33</td>
</tr>
<tr>
<td>Adult Analgesia Medical Directive</td>
<td>1-35</td>
</tr>
<tr>
<td>Opioid Toxicity Medical Directive</td>
<td>1-39</td>
</tr>
</tbody>
</table>
MEDICAL CARDIAC ARREST MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Non-traumatic cardiac arrest

CONDITIONS

**CPR**
- **AGE:** N/A
- **LOA:** Altered
- **HR:** N/A
- **RR:** N/A
- **SBP:** N/A
- **Other:** Performed in 2 minute intervals

**AED Defibrillation**
- **AGE:** ≥30 days
- **LOA:** Altered
- **HR:** N/A
- **RR:** N/A
- **SBP:** N/A
- **Other:** Shock indicated

**Manual Defibrillation**
- **AGE:** ≥30 days
- **LOA:** Altered
- **HR:** N/A
- **RR:** N/A
- **SBP:** N/A
- **Other:** VF or pulseless VT

**Epinephrine**
- **AGE:** N/A
- **LOA:** Altered
- **HR:** N/A
- **RR:** N/A
- **SBP:** N/A
- **Other:** Anaphylaxis suspected as causative event

**Medical TOR**
- **AGE:** ≥18 years
- **LOA:** Altered
- **HR:** N/A
- **RR:** N/A
- **SBP:** N/A
- **Other:** Arrest not witnessed by EMS AND No ROSC AND No shocks delivered
CONTRAINDICATIONS

CPR
Obviously dead as per BLS Standards
Meet conditions of DNR Standard

AED Defibrillation
Non-shockable rhythm

Manual Defibrillation
Rhythms other than VF or pulseless VT

Epinephrine
Allergy or sensitivity to epinephrine

Medical TOR
Arrest thought to be of non-cardiac origin

TREATMENT

Consider CPR

Consider AED defibrillation:

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>4</td>
</tr>
<tr>
<td>With Ped attenuator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without Ped attenuator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>4</td>
</tr>
</tbody>
</table>
Consider **Manual defibrillation**: (if certified and authorized)

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>First dose</th>
<th>Subsequent and max. dose(s)</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>4 J/kg</td>
<td>2 min.</td>
<td>4</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>4</td>
</tr>
</tbody>
</table>

Consider **epinephrine** (only if anaphylaxis suspected as causative event)

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>IM</td>
<td>1:1,000</td>
<td>0.01 mg/kg*</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

*The epinephrine dose may be rounded to the nearest 0.05 mg.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization, following the 3rd analysis, to consider Medical Termination of Resuscitation (TOR) (if applicable). If the BH patch fails, or the medical TOR does not apply, transport to the closest appropriate receiving hospital following ROSC or the 4th analysis.
CLINICAL CONSIDERATIONS

In unusual circumstances (e.g. pediatric patients or toxicological overdoses), consider initiating transport following the first rhythm analysis that does not result in a defibrillation being delivered.

A Paramedic may choose to move the patient to the ambulance prior to initiating the TOR if family is not coping well or the arrest occurred in a public place.

Follow the *Deceased Patient Standard* once TOR has been implemented.
TRAUMA CARDIAC ARREST MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS
Cardiac arrest secondary to severe blunt or penetrating trauma

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>AED Defibrillation</th>
<th>Manual Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE:</td>
<td>N/A</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA:</td>
<td>Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP:</td>
<td>N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other:</td>
<td>Performed in 2 minute intervals</td>
<td>Other: Shock indicated</td>
</tr>
</tbody>
</table>

Trauma TOR

AGE: ≥16 years
LOA: Altered
HR: 0
RR: 0
SBP: N/A
Other: No palpable pulses
No defibrillation delivered AND monitored HR = 0 (asystole) OR monitored HR >0 AND the closest ER ≥30 min transport time away.
CONTRAINDICATIONS

CPR
- Obviously dead as per BLS standards
- Meet conditions of DNR standard

AED Defibrillation
- Non-shockable rhythm

Manual Defibrillation
- Rhythms other than VF or pulseless VT

Trauma TOR
- Age <16 years
- Shock delivered
- Monitored HR >0 and closest ER <30 min away

TREATMENT

Consider CPR

Consider AED defibrillation:

<table>
<thead>
<tr>
<th>Age</th>
<th>With Ped attenuator</th>
<th>Without Ped attenuator</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
</tbody>
</table>

Max. single dose
- As per BH / manufacturer
- As per BH / manufacturer
- As per BH / manufacturer

Dosing interval
- 2 min.
- 2 min.
- 2 min.

Max. # of doses
- 1
- 1
- 1
Consider **Manual defibrillation**: *(if certified and authorized)*

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Initial dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>2 min.</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min.</td>
<td>1</td>
</tr>
</tbody>
</table>

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to apply the *Trauma (TOR) Termination of Resuscitation*, if applicable. If the BH patch fails, or the trauma TOR does not apply, transport to the closest appropriate receiving hospital following the first analysis/shock.

**CLINICAL CONSIDERATIONS**

If no obvious external signs of significant blunt trauma, consider medical cardiac arrest and treat according to the appropriate medical cardiac arrest directive.
TREATMENT – ALGORITHM FOR TRAUMA ARREST

**INDICATIONS:** Cardiac arrest secondary to severe blunt or penetrating trauma

CPR (throughout duration of call)

Apply defib pads to all patient ≥30 days of age - Rhythm analysis

**VF or VT**

Defibrillation: 1 shock, Max # doses = 1.

**YES**

Transport to ED

**Other monitored rhythm**

Defibrillation:

**Asystole**

YES

Transport to ED

**PEA (HR >0)**

YES

Transport to Emergency Department

Pt age ≥16 yrs

Transport to ED

TOR implemented

Drive time to closest ER ≥30 min

NO

Patch

YES

NO
HYPOTHERMIA CARDIAC ARREST MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS
Cardiac arrest secondary to severe hypothermia

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>AED Defibrillation</th>
<th>Manual Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥30 days</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Performed in 2 minute intervals</td>
<td>Other: Shock indicated</td>
<td>Other: VF or pulseless VT</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>AED Defibrillation</th>
<th>Manual Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obviously dead as per BLS standards</td>
<td>Non-shockable rhythm</td>
<td>Rhythms other than VF or pulseless VT</td>
</tr>
<tr>
<td>Meet conditions of DNR standard</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Consider **CPR**

Consider **AED defibrillation**: (with pediatric attenuator if available)

<table>
<thead>
<tr>
<th>Age</th>
<th>With Ped attenuator</th>
<th>Without Ped attenuator</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Max. single dose</th>
<th>As per BH / manufacturer</th>
<th>As per BH / manufacturer</th>
<th>As per BH / manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing interval</td>
<td>2 min.</td>
<td>2 min.</td>
<td>2 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **Manual defibrillation**:  

<table>
<thead>
<tr>
<th>Age</th>
<th>≥30 days to &lt;8 years</th>
<th>≥8 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>Initial dose</td>
<td>2 J/kg</td>
<td>As per BH / manufacturer</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>2 min.</td>
<td>2 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Transport to the closest appropriate facility without delay following the first analysis.

**CLINICAL CONSIDERATIONS**

N/A
FOREIGN BODY AIRWAY OBSTRUCTION CARDIAC ARREST MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Cardiac arrest secondary to an airway obstruction

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>AED Defibrillation</th>
<th>Manual Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥30 days</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Performed in 2 minute intervals</td>
<td>Other: Shock indicated</td>
<td>Other: VF or pulseless VT</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>AED Defibrillation</th>
<th>Manual Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obviously dead as per BLS standards</td>
<td>Non-shockable rhythm</td>
<td>Rhythms other than VF or pulseless VT</td>
</tr>
<tr>
<td>Meet conditions of DNR standard</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TREATMENT

Consider CPR
Consider foreign body removal: (utilizing BLS maneuvers)

Consider AED defibrillation:

<table>
<thead>
<tr>
<th>Age</th>
<th>With Ped attenuator</th>
<th>Without Ped attenuator</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
</tbody>
</table>

Max. single dose: As per BH / manufacturer

Dosing interval: 2 min.

Max. # of doses: 1

Consider Manual defibrillation:

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Initial dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

If the patient is in cardiac arrest following removal of the obstruction, initiate management as a medical cardiac arrest.

If the obstruction cannot be removed, transport to the closest appropriate facility without delay following the first analysis.

CLINICAL CONSIDERATIONS

N/A
NEONATAL RESUSCITATION MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Severe cardio-respiratory distress

CONDITIONS

<table>
<thead>
<tr>
<th>Resuscitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: newborn or &lt;30 days of age</td>
</tr>
<tr>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Less than full term, or meconium, or poor APGAR score</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Resuscitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear of meconium</td>
</tr>
<tr>
<td>Breathing or crying</td>
</tr>
<tr>
<td>Good muscle tone</td>
</tr>
<tr>
<td>Pink in colour</td>
</tr>
</tbody>
</table>
**TREATMENT**

**Birth:**
- Clear of *meconium?*
- Breathing or crying?
- Good muscle tone?
- Colour pink?
- Term gestation

- **YES**
  - Provide warmth
  - Position/clear airway (as necessary)
  - Dry, stimulate, reposition

- **NO**

  **30 secs**
  - Evaluate respirations, heart rate and colour

  **Apnea, gasping or HR <100**
  - Provide positive pressure ventilation (BVM) using air

  **60 secs**
  - Provide positive pressure ventilation (BVM) using air

  **HR <60**
  - Provide positive pressure ventilation (BVM/ETT) using 100% oxygen
  - Administer chest compressions
  - Initiate transport

  **HR ≥60**

  **90 secs**
  - Provide positive pressure ventilation (BVM/ETT) using 100% oxygen
  - Administer chest compressions
  - Initiate transport

**Routine care:**
- Provide warmth
- Clear airway if necessary
- Do not routinely suction
- Dry
- Ongoing evaluation

**Supportive care**
- Breathing
  - HR ≥100 + pink

**Ventilating**
- Ventilating
  - HR ≥100 + pink

---

*if meconium is present and baby not vigorous, suction mouth and pharynx and provide BVM ventilations as required and then continue with the remainder of the initial steps following birth.*
**RETURN OF SPONTANEOUS CIRCULATION (ROSC) MEDICAL DIRECTIVE**

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

**INDICATIONS**

Patient with return of spontaneous circulation (ROSC) after the resuscitation was initiated.

**CONDITIONS**

<table>
<thead>
<tr>
<th>0.9% NaCl Fluid Bolus</th>
<th>Therapeutic hypothermia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE:</strong> N/A</td>
<td><strong>AGE:</strong> males ≥ 18 years, females ≥ 50 years</td>
</tr>
<tr>
<td><strong>LOA:</strong> N/A</td>
<td><strong>LOA:</strong> Altered</td>
</tr>
<tr>
<td><strong>HR:</strong> N/A</td>
<td><strong>HR:</strong> N/A</td>
</tr>
<tr>
<td><strong>RR:</strong> N/A</td>
<td><strong>RR:</strong> N/A</td>
</tr>
<tr>
<td><strong>SBP:</strong> Hypotension</td>
<td><strong>SBP:</strong> ≥ 90 mmHg (spontaneous or following bolus administered)</td>
</tr>
<tr>
<td><strong>Other:</strong> Chest auscultation is clear</td>
<td><strong>Other:</strong> N/A</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

0.9% NaCl Fluid Bolus
- Fluid overload
- SBP ≥90 mmHg

Therapeutic hypothermia
- Traumatic cardiac arrest (blunt, penetrating or burn)
- Sepsis or serious infection suspected as cause of arrest
- Hypothermic arrest
- Known coagulopathy (medical history or medications)

TREATMENT

Consider **rapid transport**

Consider **optimizing ventilation and oxygenation:**
- Titrate oxygenation ≥94%
- Avoid hyperventilation and target an ETCO₂ of 35-40 mmHg with continuous waveform capnography (if available)

Consider **0.9% NaCl fluid bolus:** (if certified and authorized)

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 years</td>
<td>IV</td>
<td>10 ml/kg</td>
<td>Immediate</td>
<td>100 ml</td>
<td>1,000 ml</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV</td>
<td>10 ml/kg</td>
<td>Immediate</td>
<td>250 ml</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>
Consider **12-lead ECG acquisition**

Consider *Therapeutic hypothermia* (if available)

**CLINICAL CONSIDERATIONS**

The application of therapeutic hypothermia should not detract from rapid transport, optimizing ventilation and oxygenation or the management of a re-arrest.
CARDIAC ISCHEMIA MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Suspected cardiac ischemia

CONDITIONS

<table>
<thead>
<tr>
<th>ASA</th>
<th>Nitroglycerin</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: 60-159/min</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: Normotension</td>
</tr>
<tr>
<td>Other:</td>
<td>Other: Prior history of nitroglycerin use OR IV access obtained</td>
</tr>
</tbody>
</table>
**CONTRAINDICATIONS**

<table>
<thead>
<tr>
<th>ASA</th>
<th>Nitroglycerin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to ASA or NSAIDS</td>
<td>Allergy or sensitivity to nitrates</td>
</tr>
<tr>
<td>If asthmatic, no prior use of ASA</td>
<td>Phosphodiesterase inhibitor use within the previous 48 hours</td>
</tr>
<tr>
<td>Current active bleeding</td>
<td>SBP drops by one-third or more of its initial value after nitroglycerin is administered</td>
</tr>
<tr>
<td>CVA or TBI in the previous 24 hours</td>
<td>12-lead ECG compatible with Right Ventricular infarct</td>
</tr>
</tbody>
</table>

**TREATMENT**

**Consider ASA**

<table>
<thead>
<tr>
<th>Route</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
<td>160-162 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>162 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>

**Consider 12-lead ECG acquisition**
Consider nitroglycerin:

<table>
<thead>
<tr>
<th>SBP</th>
<th>≥100 mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
<td>SL</td>
</tr>
<tr>
<td>Dose</td>
<td>0.3 or 0.4 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>0.4 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>5 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>6</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

N/A
ACUTE CARDIOGENIC PULMONARY EDEMA MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Moderate to severe respiratory distress
AND
Suspected acute cardiogenic pulmonary edema

CONDITIONS

Nitroglycerin
AGE: ≥18 years
LOA: N/A
HR: 60-159/min
RR: N/A
SBP: Normotension
Other: Ascertain prior history of nitroglycerin use OR establish IV access
CONTRAINDICATIONS

Nitroglycerin
- Allergy or sensitivity to nitrates
- Phosphodiesterase inhibitor use within the previous 48 hours
- SBP drops by one-third or more of its initial value after nitroglycerin is administered

TREATMENT

Consider nitroglycerin:

<table>
<thead>
<tr>
<th>SBP 100 mmHg to &lt;140 mmHg</th>
<th>SBP ≥140 mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV or Hx</strong></td>
<td><strong>IV or Hx</strong></td>
</tr>
<tr>
<td><strong>Yes</strong></td>
<td><strong>No</strong></td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td><strong>Route</strong></td>
</tr>
<tr>
<td><strong>SL</strong></td>
<td><strong>SL</strong></td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td><strong>Dose</strong></td>
</tr>
<tr>
<td>0.3 or 0.4 mg</td>
<td>0.3 or 0.4 mg</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td><strong>Max. single dose</strong></td>
</tr>
<tr>
<td>0.4 mg</td>
<td>0.4 mg</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td><strong>Max. # of doses</strong></td>
</tr>
<tr>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

**NOTE:** Hx refers to a patient with a prior history of nitroglycerin use

Consider 12-lead ECG acquisition

CLINICAL CONSIDERATIONS

IV condition applies only to PCPs certified to the level of PCP Autonomous IV.
CARDIOGENIC SHOCK MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

STEMI-positive ECG
AND
Cardiogenic shock

CONDITIONS

0.9% NaCl Fluid Bolus

AGE: ≥18 years
LOA: N/A
HR: N/A
RR: N/A
SBP: Hypotension
Other: Clear chest on auscultation

CONTRAINDICATIONS

0.9% NaCl Fluid Bolus
N/A
TREATMENT

Consider 0.9% NaCl fluid bolus

<table>
<thead>
<tr>
<th>Age</th>
<th>≥18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
<td>IV</td>
</tr>
<tr>
<td>Infusion</td>
<td>10 ml/kg</td>
</tr>
<tr>
<td>Infusion interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Reassess every</td>
<td>250 ml</td>
</tr>
<tr>
<td>Max. volume</td>
<td>10 ml/kg</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

N/A
HYPOGLYCEMIA MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Agitation OR altered LOA OR seizure OR symptoms of stroke

CONDITIONS

<table>
<thead>
<tr>
<th>Dextrose</th>
<th>Glucagon</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE:</td>
<td>=≥2 years</td>
</tr>
<tr>
<td>LOA:</td>
<td>Altered</td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP:</td>
<td>N/A</td>
</tr>
<tr>
<td>Other:</td>
<td>Hypoglycemia</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Dextrose</th>
<th>Glucagon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to dextrose</td>
<td>Allergy or sensitivity to glucagon</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td></td>
</tr>
</tbody>
</table>

TREATMENT

Perform **glucometry**
Consider **dextrose** (if certified and authorized) or **glucagon**:

<table>
<thead>
<tr>
<th>Medication</th>
<th>Age</th>
<th>Weight</th>
<th>Concentration</th>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dextrose</strong></td>
<td>≥2 years</td>
<td>N/A</td>
<td>D50W</td>
<td>IV</td>
<td>0.5 g/kg</td>
<td>25 g (50 ml)</td>
<td>10 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(1 ml/kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glucagon</strong></td>
<td>N/A</td>
<td>&lt;25 kg</td>
<td>N/A</td>
<td>IM</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>20 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥25 kg</td>
<td>N/A</td>
<td>IM</td>
<td>1 mg</td>
<td>1 mg</td>
<td>20 min.</td>
<td>2</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

If the patient responds to dextrose or glucagon, he/she may receive oral glucose or other simple carbohydrates.

If only mild signs or symptoms are exhibited, the patient may receive oral glucose or other simple carbohydrates instead of dextrose or glucagon.

If a patient initiates an informed refusal of transport, a final set of vital signs including blood glucometry must be attempted and documented.

IV administration of dextrose applies only to PCPs certified to the level of PCP Autonomous IV.
BRONCHOCONSTRICTION MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Respiratory distress  
AND  
Suspected bronchoconstriction

CONDITIONS

<p>| Salbutamol |</p>
<table>
<thead>
<tr>
<th>AGE: N/A</th>
<th>LOA: N/A</th>
<th>HR: N/A</th>
<th>RR: N/A</th>
<th>SBP: N/A</th>
<th>Other: N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGE: N/A</td>
<td>WEIGHT: N/A</td>
<td>LOA: N/A</td>
<td>HR: N/A</td>
<td>RR: BVM ventilation required</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Epinephrine Autoinjector</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGE: N/A</td>
<td>WEIGHT: ≥10 kg</td>
<td>LOA: N/A</td>
<td>HR: N/A</td>
<td>RR: BVM ventilation required</td>
<td>SBP: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Salbutamol</th>
<th>Allergy or sensitivity to salbutamol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td>Allergy or sensitivity to epinephrine</td>
</tr>
<tr>
<td>Epinephrine Autoinjector</td>
<td>Allergy or sensitivity to epinephrine</td>
</tr>
</tbody>
</table>
### TREATMENT

Consider **salbutamol**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Dose</th>
<th>Max. Single Dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25 kg</td>
<td>MDI*</td>
<td>Up to 600 mcg</td>
<td>600 mcg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>NEB</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥25 kg</td>
<td>MDI*</td>
<td>Up to 800 mcg</td>
<td>800 mcg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>NEB</td>
<td>5 mg</td>
<td>5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1 puff=100mcg

### Consider **epinephrine**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>IM</td>
<td>1:1,000</td>
<td>0.01 mg/kg**</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥10 kg to &lt;25 kg</td>
<td>Pediatric Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.15 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>Adult Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.3 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**The epinephrine dose may be rounded to the nearest 0.05 mg.**
CLINICAL CONSIDERATIONS

Epinephrine should be the first medication administered if the patient is apneic. Salbutamol MDI may be administered subsequently using a BVM MDI adapter.

Nebulization is contraindicated in patients with a known or suspected fever or in the setting of a declared febrile respiratory illness outbreak by the local medical officer of health.

When administering salbutamol MDI, the rate of administration should be 100 mcg approximately every 4 breaths.

A spacer should be used when administering salbutamol MDI.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg.
MODERATE TO SEVERE ALLERGIC REACTION MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Exposure to a probable allergen

AND

Signs and/or symptoms of a moderate to severe allergic reaction (including anaphylaxis)

CONDITIONS

<table>
<thead>
<tr>
<th>Epinephrine</th>
<th>Epinephrine Autoinjector</th>
<th>Diphenhydramine</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: N/A</td>
<td>AGE: N/A</td>
</tr>
<tr>
<td>WEIGHT: N/A</td>
<td>WEIGHT: ≥10 kg</td>
<td>WEIGHT: ≥25 kg</td>
</tr>
<tr>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: For anaphylaxis only</td>
<td>Other: For anaphylaxis only</td>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Epinephrine</th>
<th>Epinephrine Autoinjector</th>
<th>Diphenhydramine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to epinephrine</td>
<td>Allergy or sensitivity to epinephrine</td>
<td>Allergy or sensitivity to diphenhydramine</td>
</tr>
</tbody>
</table>
Consider **epinephrine**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>IM</td>
<td>1:1,000</td>
<td>0.01 mg/kg*</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥10 kg to &lt;25 kg</td>
<td>Pediatric Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.15 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>Adult Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.3 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

*The epinephrine dose may be rounded to the nearest 0.05 mg.

Consider **diphenhydramine** (if certified and authorized):

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥25 kg to &lt;50 kg</td>
<td>25 mg</td>
<td>25 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥50 kg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

Epinephrine should be the first medication administered in anaphylaxis.

IV administration of diphenhydramine applies only to PCPs certified to the level of PCP Autonomous IV.
MANDATORY PROVINCIAL PATCH POINT:

Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg
CROUP MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Severe respiratory distress
AND
Stridor at rest
AND
Current history of URTI
AND
Barking cough OR recent history of a barking cough

CONDITIONS

Epinephrine
AGE: <8 years
LOA: N/A
HR: <200/min
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Epinephrine
Allergy or sensitivity to epinephrine
Consider *epinephrine*:

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt;1 year</th>
<th>≥1 year to 8 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>&lt;5 kg</td>
<td>≥5 kg</td>
</tr>
<tr>
<td>Route</td>
<td>NEB</td>
<td>NEB</td>
</tr>
<tr>
<td>Concentration</td>
<td>1:1,000</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Dose</td>
<td>0.5 mg</td>
<td>2.5 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>0.5 mg</td>
<td>2.5 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

The minimum initial volume for nebulization is 2.5 ml.
ADULT ANALGESIA MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Mild – Moderate Pain (Acetaminophen/Ibuprofen) OR

Mild – Severe Pain (Ketorolac)

AND

isolated hip or extremity trauma OR burns OR renal colic with prior history OR acute musculoskeletal back strain OR current history of cancer related pain.

CONDITIONS

Acetaminophen

| AGE:    | ≥18 years |
| LOA:    | Unaltered |
| HR:     | N/A       |
| RR:     | N/A       |
| SBP:    | N/A       |
| Other:  | When used for trauma patients, restricted to those with isolated hip or extremity trauma |

Ibuprofen

| AGE:    | ≥18 years |
| LOA:    | Unaltered |
| HR:     | N/A       |
| RR:     | N/A       |
| SBP:    | N/A       |
| Other:  | When used for trauma patients, restricted to those with isolated hip or extremity trauma |
**Ketorolac**

AGE: ≥18 years  
LOA: Unaltered  
HR: N/A  
RR: N/A  
SBP: Normotension  
Other: For isolated hip or extremity trauma, restricted to those who are unable to tolerate oral medications

**CONTRAINDICATIONS**

**Acetaminophen**
- Acetaminophen use within previous 4 hours
- Allergy or sensitivity to acetaminophen
- Hx of liver disease
- Active vomiting
- Unable to take oral medication

**Ibuprofen**
- NSAID or Ibuprofen use within previous 6 hours
- Allergy or sensitivity to ASA or NSAIDS
- Patient on anticoagulation therapy
- Current active bleeding
- Hx of peptic ulcer disease or GI bleed
- Pregnant
- If asthmatic, no prior use of ASA or other NSAIDs
- CVA or TBI in the previous 24 hours
- Known renal impairment
- Active vomiting
- Unable to tolerate oral medication
**Ketorolac**

- NSAID or Ibuprofen use within previous 6 hours
- Allergy or sensitivity to ASA or NSAIDs
- Patient on anticoagulation therapy
- Current active bleeding
- Hx of peptic ulcer disease or GI bleed
- Pregnant
- If asthmatic, no prior use of ASA or other NSAIDs
- CVA or TBI in the previous 24 hours
- Known renal impairment

### TREATMENT

Consider **acetaminophen**:  

<table>
<thead>
<tr>
<th>Route</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>960-1000 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>1000 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **ibuprofen**:  

<table>
<thead>
<tr>
<th>Route</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>400 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>400 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>
Consider ketorolac:

<table>
<thead>
<tr>
<th>Route</th>
<th>IM/IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>10-15 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>15 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

Whenever possible, consider co-administration of acetaminophen and ibuprofen.

In patients with isolated hip or extremity trauma, ibuprofen and acetaminophen is preferred to ketorolac except where the patient is unable to tolerate oral medications.

If ketorolac is administered, neither acetaminophen nor ibuprofen should be administered.

Suspected renal colic patients should routinely be considered for ketorolac.
OPIOID TOXICITY MEDICAL DIRECTIVE

A Primary Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Altered LOC
AND
Respiratory depression
AND
Inability to adequately ventilate
AND
Suspected opioid overdose

CONDITIONS

Naloxone
AGE: ≥18 years
LOA: Altered
HR: N/A
RR: <10/min
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Naloxone
Allergy or sensitivity to naloxone
Uncorrected hypoglycemia
TREATMENT

MANDATORY PROVINCIAL PATCH POINT:
Patch to BHP for authorization to proceed with naloxone

Consider *naloxone*:

<table>
<thead>
<tr>
<th>Route</th>
<th>SC</th>
<th>IM</th>
<th>IN</th>
<th>IV*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>Up to 0.4 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.4 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*For the IV route titrate naloxone only to restore the patient’s respiratory status*

CLINICAL CONSIDERATIONS

IV administration of naloxone applies only to PCPs certified to the level of PCP Autonomous IV.

Naloxone may unmask alternative toxidromes in mixed overdose situations (leading to: possible seizures, hypertensive crisis, etc)

Naloxone is shorter acting than many narcotics and these patients are at high risk of having a recurrence of the narcotic effect. Therefore, every effort should be made to transport the patient to hospital for ongoing monitoring. If there is a refusal of transport initiated by the patient ensure safe monitoring by an available, reliable individual.

Combative behaviour should be anticipated following naloxone administration and paramedics should protect themselves accordingly. BVM with basic airway management and oxygenation are preferred over naloxone administration.
Appendix 2

Advanced Care Paramedic Core Medical Directives
# TABLE OF CONTENTS

Medical Cardiac Arrest Medical Directive ................................................................. 2-1
Trauma Cardiac Arrest Medical Directive ................................................................. 2-7
Hypothermia Cardiac Arrest Medical Directive ......................................................... 2-11
Foreign Body Airway Obstruction Cardiac Arrest Medical Directive ....................... 2-13
Neonatal Resuscitation Medical Directive ................................................................. 2-15
Return of Spontaneous Circulation (ROSC) Medical Directive ................................. 2-17
Cardiac Ischemia Medical Directive ........................................................................... 2-20
Acute Cardiogenic Pulmonary Edema Medical Directive ........................................... 2-23
Cardiogenic Shock Medical Directive ....................................................................... 2-25
Symptomatic Bradycardia Medical Directive ........................................................... 2-27
Tachydysrhythmia Medical Directive ........................................................................ 2-30
Intravenous and Fluid Therapy Medical Directive .................................................... 2-34
Pediatric Intraosseous Medical Directive .................................................................. 2-37
Hypoglycemia Medical Directive ............................................................................... 2-39
Seizure Medical Directive .......................................................................................... 2-42
Opioid Toxicity Medical Directive ............................................................................. 2-44
Orotracheal Intubation Medical Directive .................................................................. 2-46
Bronchoconstriction Medical Directive ..................................................................... 2-49
Moderate to Severe Allergic Reaction Medical Directive ........................................ 2-52
Croup Medical Directive ........................................................................................... 2-54
Tension Pneumothorax Medical Directive ................................................................. 2-56
Pediatric Pain Medical Directive ............................................................................... 2-58
Adult Analgesia Medical Directive ............................................................................ 2-60
Hyperkalemia Medical Directive ................................................................................ 2-65
MEDICAL CARDIAC ARREST MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Non-traumatic cardiac arrest

CONDITIONS

CPR

AGE: N/A
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: Performed in 2 minute intervals

Manual Defibrillation

AGE: ≥30 days
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: VF or pulseless VT

AED Defibrillation

AGE: ≥30 days
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: Shock indicated Alternative to manual defibrillation

Epinephrine

AGE: ≥30 days
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: If anaphylaxis suspected as causative event, IM route may be used

Amiodarone

AGE: ≥30 days
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: VF or pulseless VT

Lidocaine

AGE: ≥30 days
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: VF or pulseless VT where amiodarone is not available
0.9% NaCl Fluid Bolus
AGE: N/A
LOA: Altered
HR: N/A
RR: N/A
SBP: N/A
Other: PEA
Any other rhythm where hypovolemia is suspected

CONTRAINDICATIONS

CPR
Obviously dead as per BLS Standards
Meet conditions of DNR Standard

Manual Defibrillation
Rhythms other than VF or pulseless VT

AED Defibrillation
Non-shockable rhythm

Epinephrine
Allergy or sensitivity to epinephrine

Amiodarone
Allergy or sensitivity to amiodarone

Lidocaine
Allergy or sensitivity to lidocaine
Use / Availability of amiodarone

0.9% NaCl Fluid Bolus
Fluid overload
Consider CPR

Consider **supraglottic airway insertion**: where more than OPA/NPA and BVM required and without interrupting CPR

Consider **Manual defibrillation**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>First dose</th>
<th>Subsequent and max. dose(s)</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>4 J/kg</td>
<td>2 min</td>
<td>N/A</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Consider **AED defibrillation** (alternative to manual defibrillation)

<table>
<thead>
<tr>
<th>Age</th>
<th>With Ped attenuator</th>
<th>Without Ped attenuator</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Max. single dose</th>
<th>As per BH / manufacturer</th>
<th>As per BH / manufacturer</th>
<th>As per BH / manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing interval</td>
<td>2 min</td>
<td>2 min</td>
<td>2 min</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Consider **epinephrine:**

In the event anaphylaxis is suspected as the causative event of the cardiac arrest, a single dose of 0.01 mg/kg 1:1,000 solution, to a maximum of 0.5 mg IM, may be given prior to obtaining the IV/IO.

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV / IO / CVAD</td>
<td>ETT</td>
</tr>
<tr>
<td>Solution</td>
<td>1:10,000</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Dose</td>
<td>0.01 mg/kg*</td>
<td>0.1 mg/kg</td>
</tr>
<tr>
<td>Min. single dose</td>
<td>0.1 mg</td>
<td>1 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>4 min.</td>
<td>4 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*The epinephrine dose may be rounded to the nearest 0.05 mg.

Consider **amiodarone:**

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV / IO / CVAD</td>
<td>IV / IO / CVAD</td>
</tr>
<tr>
<td>Initial Dose</td>
<td>5 mg/kg</td>
<td>300 mg</td>
</tr>
<tr>
<td>Max. initial dose</td>
<td>300 mg</td>
<td>300 mg</td>
</tr>
<tr>
<td>Repeat dose</td>
<td>5 mg/kg</td>
<td>150 mg</td>
</tr>
<tr>
<td>Max. repeat dose</td>
<td>150 mg</td>
<td>150 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>4 min.</td>
<td>4 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
Consider *lidocaine*: (if amiodarone not available)

<table>
<thead>
<tr>
<th>Age</th>
<th>IV / IO / CVAD</th>
<th>ETT</th>
<th>IV / IO / CVAD</th>
<th>ETT</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to 12 years</td>
<td>1 mg/kg</td>
<td>2 mg/kg</td>
<td>1.5 mg/kg</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>≥12 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Min. single dose**

- N/A
- N/A
- N/A
- N/A

**Dosing interval**

- 4 min.
- 4 min.
- 4 min.
- 4 min.

**Max. # of doses**

- 2
- 2
- 2
- 2

Consider **0.9% NaCl fluid bolus**:

<table>
<thead>
<tr>
<th>Age</th>
<th>IV / IO / CVAD</th>
<th>IV / IO / CVAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;12 years</td>
<td>20 ml/kg</td>
<td>20 ml/kg</td>
</tr>
<tr>
<td>≥12 years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Infusion interval**

- Immediate
- Immediate

**Reassess every**

- 100 ml
- 250 ml

**Max. volume**

- 20 ml/kg up to 2,000 ml
- 2,000 ml

Consider **intubation**: if the airway is not being adequately managed.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP following 3 rounds of epinephrine (or after 3rd analyses if no IV/IO/ETT access). If the BH patch fails, transport to the closest appropriate receiving hospital following the 4th epinephrine administration (or 4th analysis if no IV/IO/ETT access).
CLINICAL CONSIDERATIONS

In unusual circumstances (e.g. pediatric patients or toxicological overdoses), consider initiating transport following the first rhythm analysis that does not result in a defibrillation being delivered.

The IV and IO routes of medication administration are preferred over the ETT route. However, ETT administration may be used if the IV/IO routes are delayed (e.g. >5 min.)
TRAUMA CARDIAC ARREST MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Cardiac arrest secondary to severe blunt or penetrating trauma

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>Manual Defibrillation</th>
<th>AED Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥30 days</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Performed in 2 minute intervals</td>
<td>Other: VF or pulseless VT</td>
<td>Other: Shock indicated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Trauma TOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥16 years</td>
</tr>
<tr>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: 0</td>
</tr>
<tr>
<td>RR: 0</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: No palpable pulses</td>
</tr>
<tr>
<td>No defibrillation delivered <strong>AND</strong> monitored HR =0 (asystole) <strong>OR</strong> monitored HR &gt;0 <strong>AND</strong> the closest ER ≥30 min transport time away</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

**CPR**
- Obviously dead as per BLS standards
- Meet conditions of DNR standard

**Manual Defibrillation**
- Rhythms other than VF or pulseless VT

**AED Defibrillation**
- Non-shockable rhythm

**Trauma TOR**
- Age <16 years
- Shock delivered
- Monitored HR >0 and closest ER <30 min away

TREATMENT

Consider **CPR**

Consider **Manual defibrillation**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Initial dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

Advanced Life Support Patient Care Standards – Version 3.4
ACP Core Medical Directives – Appendix 2
Consider AED defibrillation (alternative to manual defibrillation)

<table>
<thead>
<tr>
<th>Age</th>
<th>With Ped attenuator</th>
<th>Without Ped attenuator</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>1 shock</td>
</tr>
</tbody>
</table>

- Max. single dose: As per BH / manufacturer
- Dosing interval: 2 min
- Max. # of doses: 1

MANDATORY PROVINCIAL PATCH POINT:

Patch to BHP for authorization to apply the Trauma (TOR) Termination of Resuscitation if applicable. If the BH patch fails, or the trauma TOR does not apply, transport to the closest appropriate receiving hospital following the first analysis/shock.

CLINICAL CONSIDERATIONS

If no obvious external signs of significant blunt trauma, consider medical cardiac arrest and treat according to the appropriate medical cardiac arrest directive.
TREATMENT – ALGORITHM FOR TRAUMA ARREST

**INDICATIONS:** Cardiac arrest secondary to severe blunt or penetrating trauma

- **CPR** (throughout duration of call)

- **Apply defib pads to all patient ≥30 days of age - Rhythm analysis**

  - **VF or VT**
    - YES: Defibrillation: 1 shock, Max # doses = 1.
    - YES: Transport to ED

  - **Other monitored rhythm**
    - YES: Asystole (Pt age ≥16 yrs)
      - YES: Drive time to closest ER ≥30 min
        - NO: Patch
          - YES: TOR implemented
        - NO: Patch
          - NO: TOR implemented
    - YES: PEA (HR >0)
      - YES: Drive time to closest ER ≥30 min
        - NO: Patch
          - YES: TOR implemented
        - NO: Patch
          - NO: TOR implemented

- **Transport to Emergency Department**
HYPOTHERMIA CARDIAC ARREST MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Cardiac arrest secondary to severe hypothermia

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>Manual Defibrillation</th>
<th>AED Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥30 days</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Performed in 2 minute intervals</td>
<td>Other:VF or pulseless VT</td>
<td>Other: Shock indicated</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>Manual Defibrillation</th>
<th>AED Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obviously dead as per BLS standards</td>
<td>Rhythms other than VF or pulseless VT</td>
<td>Non-shockable rhythm</td>
</tr>
<tr>
<td>Meet conditions of DNR standard</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Obviously dead as per BLS standards
Meet conditions of DNR standard
Rhythms other than VF or pulseless VT
Non-shockable rhythm
TREATMENT

Consider **CPR**

Consider **Manual defibrillation**:  

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Initial dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **AED defibrillation**: (alternative to manual defibrillation)  

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

Transport to the closest appropriate facility without delay following the first analysis.

CLINICAL CONSIDERATIONS

N/A
FOREIGN BODY AIRWAY OBSTRUCTION CARDIAC ARREST MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Cardiac arrest secondary to an airway obstruction

CONDITIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>Manual Defibrillation</th>
<th>AED Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥30 days</td>
<td>AGE: ≥30 days</td>
</tr>
<tr>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Performed in 2 minute intervals</td>
<td>Other: VF or pulseless VT</td>
<td>Other: Shock indicated</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>CPR</th>
<th>Manual Defibrillation</th>
<th>AED Defibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obviously dead as per BLS Standards</td>
<td>Rhythms other than VF or pulseless VT</td>
<td>Non-shockable rhythm</td>
</tr>
<tr>
<td>Meet conditions of DNR Standard</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TREATMENT

Consider CPR
Consider **foreign body removal**: (utilizing BLS maneuvers and/or laryngoscope and Magill forceps)

Consider **Manual defibrillation**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Initial dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years</td>
<td>1 shock</td>
<td>2 J/kg</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **AED defibrillation**: (alternative to manual defibrillation)

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30 days to &lt;8 years With Ped attenuator</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>Without Ped attenuator</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
<tr>
<td>≥8 years</td>
<td>1 shock</td>
<td>As per BH / manufacturer</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

If the obstruction cannot be removed, transport to the closest appropriate facility without delay following the first analysis.

If the patient is in cardiac arrest following removal of the obstruction, initiate management as a medical cardiac arrest.

**CLINICAL CONSIDERATIONS**

N/A
NEONATAL RESUSCITATION MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Severe cardio-respiratory distress

CONDITIONS

Resuscitation

<table>
<thead>
<tr>
<th>AGE:</th>
<th>newborn or &lt;30 days of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOA:</td>
<td>N/A</td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP:</td>
<td>N/A</td>
</tr>
<tr>
<td>Other:</td>
<td>Less than full term OR meconium OR poor APGAR score</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

Resuscitation

- Clear of meconium
- Breathing or crying
- Good muscle tone
- Pink in colour
TREATMENT

Birth:
Clear of *meconium?
Breathing or crying?
Good muscle tone?
Colour pink?
Term gestation

Routinely care:
Provide warmth
Clear airway if necessary
Do not routinely suction
Dry
Ongoing evaluation

NO

Provide warmth
Position/clear airway (as necessary)
Dry, stimulate, reposition

YES

Breathing
HR ≥100 + pink

Ventilating
HR ≥100 + pink

Supportive care

Supportive care

Evaluate respirations, heart rate and colour

30 secs

Apnea, gasping or HR <100

60 secs

Provide positive pressure ventilation (BVM) using air

HR < 60
HR ≥ 60

Provide positive pressure ventilation (BVM/ETT) using 100% oxygen
Administer chest compressions

HR < 60
HR ≥ 60

Epinephrine: 0.01 mg/kg (0.1 ml/kg) 1:10,000 IV/IO OR 0.1 mg/kg (1 ml/kg) 1:10,000 ETT q 4 minutes.
Initiate transport prior to the 3rd dose if possible.

*if meconium is present and baby not vigorous, suction mouth and pharynx, consider ETT and provide BVM ventilations as required and then continue with the remainder of the initial steps following birth.
RETURN OF SPONTANEOUS CIRCULATION (ROSC) MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Patient with return of spontaneous circulation (ROSC) after the resuscitation was initiated.

CONDITIONS

<table>
<thead>
<tr>
<th>0.9% NaCl Fluid Bolus</th>
<th>Dopamine</th>
<th>Therapeutic hypothermia</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: ≥18 years</td>
<td>AGE: males ≥18 years, females ≥50 years</td>
</tr>
<tr>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: Hypotension</td>
<td>SBP: Hypotension</td>
<td>SBP: ≥90 mmHg (spontaneous, following bolus administered or with dopamine)</td>
</tr>
<tr>
<td>Other: Chest auscultation is clear</td>
<td>Other: N/A</td>
<td>Other: N/A</td>
</tr>
</tbody>
</table>
# CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>0.9% NaCl Fluid Bolus</th>
<th>Dopamine</th>
<th>Therapeutic hypothermia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluid overload</td>
<td>Allergy or sensitivity to dopamine</td>
<td>Traumatic cardiac arrest (blunt, penetrating or burn)</td>
</tr>
<tr>
<td>SBP ≥90 mmHg</td>
<td>Tachydysrhythmias excluding sinus tachycardia</td>
<td>Sepsis or serious infection suspected as cause of arrest</td>
</tr>
<tr>
<td></td>
<td>Mechanical shock states</td>
<td>Hypothermic arrest</td>
</tr>
<tr>
<td></td>
<td>Hypovolemia</td>
<td>Known coagulopathy (medical history or medications)</td>
</tr>
<tr>
<td></td>
<td>Pheochromocytoma</td>
<td></td>
</tr>
</tbody>
</table>

# TREATMENT

- Consider **rapid transport**

- Consider **optimizing ventilation and oxygenation**:
  - Titrate oxygenation ≥94%
  - Avoid hyperventilation and target an ETCO₂ of 35-40 mmHg with continuous waveform capnography (if available)
Consider **0.9% NaCl fluid bolus**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 years</td>
<td>IV</td>
<td>10 ml/kg</td>
<td>Immediate</td>
<td>100 ml</td>
<td>1,000 ml</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV</td>
<td>10 ml/kg</td>
<td>Immediate</td>
<td>250 ml</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>

NOTE: Consider dopamine:

<table>
<thead>
<tr>
<th>Route</th>
<th>Initial Infusion Rate</th>
<th>Titration increment</th>
<th>Titration interval</th>
<th>Max infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>5 mcg/kg/min</td>
<td>5 mcg/kg/min</td>
<td>5 min.</td>
<td>20 mcg/kg/min</td>
</tr>
</tbody>
</table>

NOTE: Titrate dopamine to achieve a systolic BP of 90-110 mmHg. If discontinuing dopamine electively, do so gradually over 5-10 minutes.

Consider **12-lead ECG acquisition**

Consider **Therapeutic hypothermia** (if available)

**CLINICAL CONSIDERATIONS**

The application of therapeutic hypothermia should not detract from rapid transport, optimizing ventilation and oxygenation or the management of a re-arrest.
**CARDIAC ISCHEMIA MEDICAL DIRECTIVE**

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

### INDICATIONS

Suspected cardiac ischemia

### CONDITIONS

<table>
<thead>
<tr>
<th></th>
<th>ASA</th>
<th>Nitroglycerin</th>
<th>Morphine</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE:</td>
<td>≥18 years</td>
<td>≥18 years</td>
<td>≥18 years</td>
</tr>
<tr>
<td>LOA:</td>
<td>Unaltered</td>
<td>Unaltered</td>
<td>Unaltered</td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
<td>60-159/min</td>
<td>N/A</td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP:</td>
<td>N/A</td>
<td>Normotension</td>
<td>Normotension</td>
</tr>
<tr>
<td>Other:</td>
<td>Able to chew and swallow</td>
<td>Prior history of nitroglycerin use or IV access obtained</td>
<td>N/A</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

**ASA**
- Allergy or sensitivity to ASA or NSAIDS
- If asthmatic, no prior use of ASA
- Current active bleeding
- CVA or TBI in the previous 24 hours

**Nitroglycerin**
- Allergy or sensitivity to nitrates
- Phosphodiesterase inhibitor use within the previous 48 hours
- SBP drops by one third or more of its initial value after nitroglycerin is administered
- 12-lead ECG compatible with Right Ventricular infarct

**Morphine**
- Allergy or sensitivity to morphine
- Injury to the head or chest or abdomen OR pelvis
- SBP drops by one-third or more of its initial value after morphine is administered

TREATMENT

Consider **ASA**

**Route**

<table>
<thead>
<tr>
<th>Dose</th>
<th>160-162 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max. single dose</td>
<td>162 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **12-lead ECG acquisition**
Consider *nitroglycerin*:  

<table>
<thead>
<tr>
<th>SBP</th>
<th>≥100 mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Route</strong></td>
</tr>
<tr>
<td></td>
<td><em>SL</em></td>
</tr>
<tr>
<td>Dose</td>
<td>0.3 or 0.4 mg</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td>0.4 mg</td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>5 min.</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>6</td>
</tr>
</tbody>
</table>

Consider *morphine* (after the third dose of nitroglycerin or if nitroglycerin is contraindicated):  

<table>
<thead>
<tr>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>IV</em></td>
</tr>
<tr>
<td>Dose</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

N/A
ACUTE CARDIOGENIC PULMONARY EDEMA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Moderate to severe respiratory distress

AND

Suspected acute cardiogenic pulmonary edema

CONDITIONS

Nitroglycerin

AGE: ≥18 years
LOA: N/A
HR: 60-159/min
RR: N/A
SBP: Normotension
Other: Ascertain prior history of nitroglycerin use
OR establish IV access
CONTRAINDICATIONS

Nitroglycerin
Allergy or sensitivity to nitrates
Phosphodiesterase inhibitor use within the previous 48 hours
SBP drops by one third or more of its initial value after nitroglycerin is administered

TREATMENT

Consider nitroglycerin:

<table>
<thead>
<tr>
<th>SBP</th>
<th>IV or Hx</th>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mmHg to &lt;140 mmHg</td>
<td>Yes</td>
<td>SL</td>
<td>0.3 or 0.4 mg</td>
<td>0.4 mg</td>
<td>5 min.</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>SL</td>
<td>0.3 or 0.4 mg</td>
<td>0.4 mg</td>
<td>5 min.</td>
<td>6</td>
</tr>
<tr>
<td>≥140 mmHg</td>
<td>Yes</td>
<td>SL</td>
<td>0.6 or 0.8 mg</td>
<td>0.8 mg</td>
<td>5 min.</td>
<td>6</td>
</tr>
</tbody>
</table>

NOTE: Hx refers to a patient with a prior history of nitroglycerin use

Consider 12-lead ECG acquisition

CLINICAL CONSIDERATIONS

N/A
CARDIOGENIC SHOCK MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

STEMI-positive ECG
AND
Cardiogenic shock

CONDITIONS

0.9% NaCl Fluid Bolus
- AGE: ≥18 years
- LOA: N/A
- HR: N/A
- RR: N/A
- SBP: Hypotension
- Other: Clear chest on auscultation

Dopamine
- AGE: ≥18 years
- LOA: N/A
- HR: N/A
- RR: N/A
- SBP: Hypotension
- Other: N/A

CONTRAINDICATIONS

0.9% NaCl Fluid Bolus
- N/A

Dopamine
- Allergy or sensitivity to dopamine
- Tachydysrhythmias excluding sinus tachycardia
- Mechanical shock states
- Hypovolemia
- Pheochromocytoma
TREATMENT

Consider **0.9% NaCl fluid bolus**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥18 years</td>
<td>IV</td>
<td>IO</td>
</tr>
<tr>
<td>Infusion</td>
<td>10 ml/kg</td>
<td>10 ml/kg</td>
</tr>
<tr>
<td>Infusion interval</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Reassess every</td>
<td>250 ml</td>
<td>250 ml</td>
</tr>
<tr>
<td>Max. volume</td>
<td>10 ml/kg</td>
<td>10 ml/kg</td>
</tr>
</tbody>
</table>

**NOTE:** If NaCl bolus contraindicated due to pulmonary crackles, consider dopamine.

Consider **dopamine**:

<table>
<thead>
<tr>
<th>Route</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial infusion rate</td>
<td>5 mcg/kg/min.</td>
</tr>
<tr>
<td>Titration increment</td>
<td>5 mcg/kg/min.</td>
</tr>
<tr>
<td>Titration interval</td>
<td>5 min.</td>
</tr>
<tr>
<td>Max. infusion rate</td>
<td>20 mcg/kg/min.</td>
</tr>
</tbody>
</table>

**NOTE:** Titrate dopamine to achieve a systolic BP of 90-110 mmHg. If discontinuing dopamine electively, do so gradually over 5-10 minutes.

CLINICAL CONSIDERATIONS

Contact BHP if patient is bradycardic.
SYMPTOMATIC BRADYCARDIA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Bradycardia
AND
Hemodynamic instability

CONDITIONS

- **Atropine**
  - AGE: ≥18 years
  - LOA: N/A
  - HR: <50/min
  - RR: N/A
  - SBP: Hypotension
  - Other: N/A

- **Transcutaneous Pacing**
  - AGE: ≥18 years
  - LOA: N/A
  - HR: <50/min
  - RR: N/A
  - SBP: Hypotension
  - Other: N/A

- **Dopamine**
  - AGE: ≥18 years
  - LOA: N/A
  - HR: <50/min
  - RR: N/A
  - SBP: Hypotension
  - Other: N/A
CONTRAINDICATIONS

**Atropine**
- Allergy or sensitivity to atropine
- Hemodynamic stability
- Hypothermia
- History of heart transplant

**Transcutaneous Pacing**
- Hemodynamic stability
- Hypothermia

**Dopamine**
- Allergy or sensitivity to dopamine
- Tachydysrhythmias excluding sinus tachycardia
- Mechanical shock states
- Hypovolemia
- Pheochromocytoma

TREATMENT

Consider *Rhythm determination*

Consider *12-lead ECG acquisition* (if this won’t delay therapy)

Consider *atropine*:

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>5 min.</td>
<td>2</td>
</tr>
</tbody>
</table>

**MANDATORY PROVINCIAL PATCH POINT**:  
Patch to BHP for authorization to proceed with transcutaneous pacing and/or a dopamine infusion.

Consider *transcutaneous pacing*
Consider **dopamine**:

<table>
<thead>
<tr>
<th>Route</th>
<th>(\text{Initial infusion rate})</th>
<th>5 mcg/kg/min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\text{IV})</td>
<td>(\text{Titration increment})</td>
<td>5 mcg/kg/min.</td>
</tr>
<tr>
<td>(\text{Titration interval})</td>
<td>5 min.</td>
<td></td>
</tr>
<tr>
<td>(\text{Max. infusion rate})</td>
<td>20 mcg/kg/min.</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Titrate dopamine to achieve a systolic BP of 90-110 mmHg. If discontinuing dopamine electively, do so gradually over 5-10 minutes.

**CLINICAL CONSIDERATIONS**

Atropine may be beneficial in the setting of sinus bradycardia, atrial fibrillation, first degree AV block, or second-degree Type I AV block.

A single dose of atropine should be considered for second degree Type II or third degree AV blocks with fluid bolus while preparing for TCP OR if there is a delay in implementing TCP OR if TCP is unsuccessful.

The dopamine infusion should be initiated at 5 mcg/kg/min. and titrated upward to effect in increments of 5 mcg/kg/min every 5 minutes up to a maximum of 20 mcg/kg/min. The desired effect is a SBP of 90-110 mmHg.
TACHYDYSRHYTHMIA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Symptomatic Tachydysrhythmia

CONDITIONS

**Valsalva Maneuver**
- AGE: ≥18 years
- LOA: Unaltered
- HR: ≥150/min
- RR: N/A
- SBP: Normotension
- Other: Narrow complex and regular rhythm

**Adenosine**
- AGE: ≥18 years
- LOA: Unaltered
- HR: ≥150/min
- RR: N/A
- SBP: Normotension
- Other: Narrow complex and regular rhythm

**Amiodarone**
- AGE: ≥18 years
- LOA: Unaltered
- HR: ≥120/min
- RR: N/A
- SBP: Normotension
- Other: Wide complex and regular rhythm

**Lidocaine**
- AGE: ≥18 years
- LOA: Unaltered
- HR: ≥120/min
- RR: N/A
- SBP: Normotension
- Other: Wide complex and regular rhythm

**Synchronized Cardioversion**
- AGE: ≥18 years
- LOA: N/A
- HR: ≥120/min (wide) or ≥150/min (narrow)
- RR: N/A
- SBP: Hypotension
- Other: Altered mental status, ongoing chest pain, other signs of shock
## CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Valsalva Maneuver</th>
<th>Adenosine</th>
<th>Amiodarone</th>
</tr>
</thead>
</table>
| Sinus tachycardia or atrial fibrillation or atrial flutter | Allergy or sensitivity to adenosine  
Sinus tachycardia or atrial fibrillation or atrial flutter  
Patient taking dipyridamole or carbamazepine  
Bronchoconstriction on exam | Allergy or sensitivity to amiodarone |

<table>
<thead>
<tr>
<th>Lidocaine</th>
<th>Synchronized Cardioversion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to lidocaine</td>
<td>N/A</td>
</tr>
</tbody>
</table>

## TREATMENT

- Consider **Rhythm determination**: Confirm regularity
- Consider **12 lead ECG acquisition**: To confirm QRS width (if this won’t delay therapy)
- Consider **valsalva maneuver**:
  - Perform a maximum of two attempts lasting 10 to 20 seconds duration each.
Consider **adenosine**:

<table>
<thead>
<tr>
<th>Route</th>
<th>Initial Dose</th>
<th>Second dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV</strong></td>
<td>6 mg</td>
<td>12 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>2 min</td>
<td></td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2 doses</td>
<td></td>
</tr>
</tbody>
</table>

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to proceed with amiodarone or lidocaine or if monomorphic wide complex regular rhythm for adenosine.

Consider **amiodarone** (if available) **OR lidocaine**:

<table>
<thead>
<tr>
<th>Drug</th>
<th><strong>Amiodarone</strong></th>
<th><strong>Lidocaine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route</strong></td>
<td><strong>IV</strong>*</td>
<td><strong>IV</strong></td>
</tr>
<tr>
<td>First Dose</td>
<td>150 mg</td>
<td>1.5 mg/kg</td>
</tr>
<tr>
<td>Subsequent Dose(s)</td>
<td>150 mg</td>
<td>0.75 mg/kg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>150 mg</td>
<td>150 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>10 min</td>
<td>10 min</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

*Amiodarone should be administered by IV infusion over 10 min.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to proceed with synchronized cardioversion.
Consider *synchronized cardioversion*:

Administer up to three synchronized shocks in accordance with BHP direction and energy settings. *(In the setting of a patch failure, the energy settings to be used are 100 J, 200 J and the maximum manufacturer setting.)*

**CLINICAL CONSIDERATIONS**

N/A
INTRAVENOUS AND FLUID THERAPY MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Actual or potential need for intravenous medication OR fluid therapy

CONDITIONS

<table>
<thead>
<tr>
<th>IV</th>
<th>0.9% NaCl Fluid Bolus</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: N/A</td>
</tr>
<tr>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: Hypotension</td>
</tr>
<tr>
<td>Other: N/A</td>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>IV</th>
<th>0.9% NaCl Fluid Bolus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected fracture proximal to the access site.</td>
<td>Signs of fluid overload</td>
</tr>
</tbody>
</table>
TREATMENT

Consider IV cannulation

Consider 0.9% NaCl maintenance infusion

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 years</td>
<td>IV / IO / CVAD</td>
<td>15 ml/hr</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV / IO / CVAD</td>
<td>30-60 ml/hr</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

MANDATORY PROVINCIAL PATCH POINT:

Patch to BHP for authorization to administer IV NaCl bolus to patients <12 years with suspected Diabetic Ketoacidosis (DKA)

Consider 0.9% NaCl fluid bolus:

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 years</td>
<td>IV / IO / CVAD</td>
<td>20 ml/kg</td>
<td>Immediate</td>
<td>100 ml</td>
<td>20 ml/kg up to 2,000 ml</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV / IO / CVAD</td>
<td>20 ml/kg</td>
<td>Immediate</td>
<td>250 ml</td>
<td>2,000 ml</td>
</tr>
</tbody>
</table>

*The maximal volume of NaCl is lower for patients in cardiogenic shock.
CLINICAL CONSIDERATIONS

“PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The ACP will perform all IV further therapy in accordance with the Intravenous and Fluid Therapy Medical Directive once intravenous access is obtained. PCPs certified in PCP Assist IV are not authorized to administer IV fluid or medication therapy.

Adult IO and CVAD procedures are auxiliary Medical Directives described elsewhere. Fluid administration via the IO or CVAD routes only apply to paramedics certified and authorized to perform these procedures.

Microdrips and or volume control administration sets should be considered when IV access is indicated for patients less than 12 years of age.
PEDIATRIC INTRAOSSEOUS MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Actual or potential need for intravenous medication OR fluid therapy

AND

Intravenous access is unobtainable

AND

Cardiac arrest or near-arrest state

CONDITIONS

<table>
<thead>
<tr>
<th>IO</th>
<th>AGE:</th>
<th>&lt;12 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOA:</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>SBP:</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

CONTRAINDICATION

<table>
<thead>
<tr>
<th>IO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fracture or crush injuries or suspected or known replacement / prosthesis proximal to the access site.</td>
</tr>
</tbody>
</table>
### TREATMENT

Consider *IO access*

### CLINICAL CONSIDERATIONS

N/A
HYPOGLYCEMIA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Agitation OR altered LOA OR seizure OR symptoms of stroke

CONDITIONS

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dextrose</th>
<th>Glucagon</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>LOA</td>
<td>Altered</td>
<td>Altered</td>
</tr>
<tr>
<td>HR</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>RR</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Other</td>
<td>Hypoglycemia</td>
<td>Hypoglycemia</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dextrose</th>
<th>Glucagon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to dextrose</td>
<td>Allergy or sensitivity to glucagon</td>
<td></td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TREATMENT

Perform **glucometry**
Consider *dextrose or glucagon*:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Age</th>
<th>Weight</th>
<th>Concentration</th>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dextrose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;30 days</td>
<td>N/A</td>
<td><em>D10W</em></td>
<td>IV</td>
<td>0.2 g/kg</td>
<td>5 g (50 ml)</td>
<td>10 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>≥30 days to &lt;2 years</td>
<td>N/A</td>
<td><em>D25W</em></td>
<td>IV</td>
<td>0.5 g/kg</td>
<td>10 g (40 ml)</td>
<td>10 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>≥2 years</td>
<td>N/A</td>
<td><em>D50W</em></td>
<td>IV</td>
<td>0.5 g/kg (1 ml/kg)</td>
<td>25 g (50 ml)</td>
<td>10 min.</td>
<td>2</td>
</tr>
<tr>
<td><strong>Glucagon</strong></td>
<td></td>
<td></td>
<td></td>
<td>IM</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>20 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>&lt;25 kg</td>
<td>N/A</td>
<td>IM</td>
<td>1.0 mg</td>
<td>1.0 mg</td>
<td>20 min.</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>≥25 kg</td>
<td>N/A</td>
<td>N/A</td>
<td>IM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Advanced Life Support Patient Care Standards – Version 3.4*

*ACP Core Medical Directives – Appendix 2*
CLINICAL CONSIDERATIONS

If the patient responds to dextrose or glucagon, he/she may receive oral glucose or other simple carbohydrates.

If only mild signs or symptoms are exhibited, the patient may receive oral glucose or other simple carbohydrates instead of dextrose or glucagon.

If a patient initiates an informed refusal of transport, a final set of vital signs including blood glucometry must be attempted.
SEIZURE MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Active generalized motor seizure

CONDITIONS

<table>
<thead>
<tr>
<th>Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
</tr>
<tr>
<td>LOA: Unresponsive</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to midazolam</td>
</tr>
<tr>
<td>Hypoglycemia</td>
</tr>
</tbody>
</table>
TREATMENT

Consider *midazolam*:

<table>
<thead>
<tr>
<th>Route</th>
<th>IV</th>
<th>IM</th>
<th>IN</th>
<th>Buccal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>0.1 mg/kg</td>
<td>0.2 mg/kg</td>
<td>0.2 mg/kg</td>
<td>0.2 mg/kg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>5.0 mg</td>
<td>10 mg</td>
<td>10 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>5 min.</td>
<td>5 min.</td>
<td>5 min.</td>
<td>5 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

Conditions such as cardiac arrest and hypoglycemia often present as seizure and should be considered by a paramedic.
OPIOID TOXICITY MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Altered LOC  
AND  
Respiratory depression  
AND  
Suspected opioid overdose

CONDITIONS

Naloxone

AGE: ≥18 years  
LOA: Altered  
HR: N/A  
RR: <10/min  
SBP: N/A  
Other: N/A

CONTRAINDICATIONS

Naloxone

Allergy or sensitivity to naloxone  
Uncorrected hypoglycemia
TREATMENT

**MANDATORY PROVINCIAL PATCH POINT:**
Patch to BHP for authorization to proceed with naloxone

Consider **naloxone**:

<table>
<thead>
<tr>
<th>Route</th>
<th>SC</th>
<th>IM</th>
<th>IN</th>
<th>IV*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>Up to 0.4 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.8 mg</td>
<td>0.4 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*For the IV route, titrate naloxone only to restore the patient’s respiratory status.

CLINICAL CONSIDERATIONS

N/A
OROTRACHEAL INTUBATION MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Need for ventilatory assistance or airway control

AND

Other airway management is inadequate or ineffective

CONDITIONS

**Lidocaine Spray**

- AGE: N/A
- LOA: N/A
- HR: N/A
- RR: N/A
- SBP: N/A
- Other: Orotracheal Intubation

**Orotracheal Intubation**

- AGE: N/A
- LOA: N/A
- HR: N/A
- RR: N/A
- SBP: N/A
- Other: N/A

CONTRAINDICATIONS

**Lidocaine**

- Allergy or sensitivity to lidocaine
- Unresponsive patient

**Orotracheal Intubation**

- Age <50 years AND current episode of asthma exacerbation AND not in or near cardiac arrest.
TREATMENT

Consider topical **lidocaine** spray (to the hypopharynx) for “awake” orotracheal intubation:

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TOPICAL</td>
<td></td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td>10 mg/spray</td>
</tr>
<tr>
<td><strong>Max. dose</strong></td>
<td>5mg/kg</td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>20 sprays</td>
</tr>
</tbody>
</table>

Consider **orotracheal intubation**: with or without intubation facilitation devices. The maximum number of intubation attempts is 2.

Confirm **orotracheal tube placement**:

<table>
<thead>
<tr>
<th>Method</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Secondary</td>
</tr>
<tr>
<td>Visualization</td>
<td>ETCO₂</td>
</tr>
<tr>
<td>Auscultation</td>
<td>EDD</td>
</tr>
<tr>
<td>Chest rise</td>
<td>Other</td>
</tr>
</tbody>
</table>
CLINICAL CONSIDERATIONS

An intubation attempt is defined as insertion of the laryngoscope blade into the mouth for the purposes of intubation.

The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2).

At least two primary and one secondary ETT placement confirmation methods must be used.

If the patient has a pulse, an ETCO₂ device (quantitative or qualitative) must be used for ETT placement confirmation.

Additional secondary ETT placement confirmation devices may be authorized by the local medical director.

ETT placement must be reconfirmed immediately after every patient movement.
**BRONCHOCONSTRICTION MEDICAL DIRECTIVE**

*An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.*

**INDICATIONS**

Respiratory distress

**AND**

Suspected bronchoconstriction

**CONDITIONS**

**Salbutamol**
- AGE: N/A
- LOA: N/A
- HR: N/A
- RR: N/A
- SBP: N/A
- Other: N/A

**Epinephrine**
- AGE: N/A
- WEIGHT: N/A
- LOA: N/A
- HR: N/A
- RR: BVM ventilation required
- SBP: N/A
- Other: Hx of asthma

**Epinephrine Autoinjector**
- AGE: N/A
- WEIGHT: ≥10 kg
- LOA: N/A
- HR: N/A
- RR: BVM ventilation required
- SBP: N/A
- Other: Hx of asthma

**CONTRAINDICATIONS**

**Salbutamol**
- Allergy or sensitivity to salbutamol

**Epinephrine**
- Allergy or sensitivity to epinephrine

**Epinephrine Autoinjector**
- Allergy or sensitivity to epinephrine
## TREATMENT

Consider **salbutamol**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25 kg</td>
<td>MDI*</td>
<td>Up to 600 mcg (6 puffs)</td>
<td>600 mcg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>NEB</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>MDI*</td>
<td>Up to 800 mcg (8 puffs)</td>
<td>800 mcg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>NEB</td>
<td>5 mg</td>
<td>5 mg</td>
<td>5-15 min. PRN</td>
<td>3</td>
</tr>
</tbody>
</table>

*1 puff=100mcg

Consider **epinephrine**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td>IM</td>
<td>1:1,000</td>
<td>0.01 mg/kg**</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥10 kg to &lt;25 kg</td>
<td>Pediatric Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.15 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>Adult Autoinjector</td>
<td>1:1,000</td>
<td>1 injection (0.3 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**The epinephrine dose may be rounded to the nearest 0.05 mg.

## CLINICAL CONSIDERATIONS

Epinephrine should be the first drug administered if the patient is apneic. Salbutamol MDI may be administered subsequently using a BVM MDI adapter.
Nebulization is contraindicated in patients with a known or suspected fever or in the setting of a declared febrile respiratory illness outbreak by the local medical officer of health.

When administering salbutamol MDI, the rate of administration should be 100 mcg approximately every 4 breaths.

A spacer should be used when administering salbutamol MDI.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to use pediatric autoinjector for patients <10 kg.
MODERATE TO SEVERE ALLERGIC REACTION MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Exposure to a probable allergen

AND

Signs and/or symptoms of a moderate to severe allergic reaction (including anaphylaxis)

CONDITIONS

- **Epinephrine**
  - AGE: N/A
  - WEIGHT: N/A
  - LOA: N/A
  - HR: N/A
  - RR: N/A
  - SBP: N/A
  - Other: For anaphylaxis only

- **Epinephrine Autoinjector**
  - AGE: N/A
  - WEIGHT: ≥10 kg
  - LOA: N/A
  - HR: N/A
  - RR: N/A
  - SBP: N/A
  - Other: For anaphylaxis only

- **Diphenhydramine**
  - AGE: N/A
  - WEIGHT: ≥25 kg
  - LOA: N/A
  - HR: N/A
  - RR: N/A
  - SBP: N/A
  - Other: N/A

CONTRAINDICATIONS

- **Epinephrine**
  - Allergy or sensitivity to epinephrine

- **Epinephrine Autoinjector**
  - Allergy or sensitivity to epinephrine

- **Diphenhydramine**
  - Allergy or sensitivity to diphenhydramine
TREATMENT

Consider **epinephrine**:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>IM</td>
<td>1:1,000</td>
<td>0.01 mg/kg*</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥10 kg to &lt;25 kg</td>
<td>IM</td>
<td>1:1,000</td>
<td>1 injection (0.15 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>IM</td>
<td>1:1,000</td>
<td>1 injection (0.3 mg)</td>
<td>1 injection</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

*The epinephrine dose may be rounded to the nearest 0.05 mg.

Consider **diphenhydramine** (if available):

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥25 kg to &lt;50 kg</td>
<td>IV</td>
<td>25 mg</td>
<td>25 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥25 kg to &lt;50 kg</td>
<td>IM</td>
<td>25 mg</td>
<td>25 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥50 kg</td>
<td>IV</td>
<td>50 mg</td>
<td>50 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥50 kg</td>
<td>IM</td>
<td>50 mg</td>
<td>50 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

Epinephrine should be the first drug administered in anaphylaxis.

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to use pediatric autoinjector for patients <10kg.
CROUP MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Severe respiratory distress

AND

Stridor at rest

AND

Current history of URTI

AND

Barking cough OR recent history of a barking cough

CONDITIONS

Epinephrine

<table>
<thead>
<tr>
<th>AGE</th>
<th>&lt;8 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOA</td>
<td>N/A</td>
</tr>
<tr>
<td>HR</td>
<td>&lt;200/min</td>
</tr>
<tr>
<td>RR</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP</td>
<td>N/A</td>
</tr>
<tr>
<td>Other</td>
<td>N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Epinephrine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to epinephrine</td>
</tr>
</tbody>
</table>
Consider *epinephrine*:

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight</th>
<th>Route</th>
<th>Concentration</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 year</td>
<td>&lt;5 kg</td>
<td>NEB</td>
<td>1:1,000</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>≥5 kg</td>
<td>NEB</td>
<td>1:1,000</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
<tr>
<td>≥1 year to &lt;8 years</td>
<td>N/A</td>
<td>NEB</td>
<td>1:1,000</td>
<td>5 mg</td>
<td>5 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

The minimum initial volume for nebulization is 2.5 ml.
TENSION PNEUMOTHORAX MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Suspected tension pneumothorax

AND

Critically ill OR VSA

AND

Absent or severely diminished breath sounds on the affected side(s)

CONDITIONS

Needle Thoracostomy

AGE: N/A
LOA: N/A
HR: N/A
RR: N/A
SBP: Hypotension or VSA
Other: N/A

CONTRAINDICATIONS

Needle Thoracostomy
N/A
TREATMENT

**MANDATORY PROVINCIAL PATCH POINT:**
Patch to BHP for authorization to perform needle thoracostomy

Consider *needle thoracostomy*

CLINICAL CONSIDERATIONS

Needle thoracostomy may only be performed at the second intercostal space in the midclavicular line.
An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

**INDICATIONS**

Severe pain

**AND**

Isolated hip OR extremity fractures or dislocations OR major burns OR current history of cancer related pain

**CONDITIONS**

<table>
<thead>
<tr>
<th>Morphine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE:</strong> &lt;18 years</td>
</tr>
<tr>
<td><strong>LOA:</strong> Unaltered</td>
</tr>
<tr>
<td><strong>HR:</strong> ≥60/min</td>
</tr>
<tr>
<td><strong>RR:</strong> N/A</td>
</tr>
<tr>
<td><strong>SBP:</strong> Normotension</td>
</tr>
<tr>
<td><strong>Other:</strong> N/A</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

Morphine
- Allergy or sensitivity to morphine
- Injury to the head or chest or abdomen or pelvis
- SBP drops by one-third or more of its initial value after morphine is administered

TREATMENT

MANDATORY PROVINCIAL PATCH POINT:
Patch to BHP for authorization and dosage verification before administering the medication for children <8 years.

Consider morphine:

<table>
<thead>
<tr>
<th>Route</th>
<th>0.05 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>3 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>3 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>5 min.</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

N/A
ADULT ANALGESIA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

**INDICATIONS**

Mild – Moderate Pain (Acetaminophen/Ibuprofen) OR

Mild – Severe Pain (Ketorolac) AND/OR

Moderate – Severe Pain (Morphine)

AND

trauma OR burns OR renal colic with prior history OR acute musculoskeletal back strain OR current history of cancer related pain.

**CONDITIONS**

<table>
<thead>
<tr>
<th>Acetaminophen</th>
<th>Ibuprofen</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: When used for trauma patients, restricted to those with isolated hip or extremity trauma</td>
<td>Other: When used for trauma patients, restricted to those with isolated hip or extremity trauma</td>
</tr>
</tbody>
</table>
Ketorolac
AGE: ≥18 years
LOA: Unaltered
HR: N/A
RR: N/A
SBP: Normotension
Other: When used for trauma patients, restricted to those with isolated hip / extremity trauma AND who are unable to tolerate oral medications

Morphine
AGE: ≥18 years
LOA: Unaltered
HR: N/A
RR: N/A
SBP: Normotension
Other: N/A
CONTRAINDICATIONS

**Acetaminophen**
- Acetaminophen use within previous 4 hours
- Allergy or sensitivity to acetaminophen
- Hx of liver disease
- Active vomiting
- Unable to tolerate oral medication

**Ibuprofen**
- NSAID or Ibuprofen use within previous 6 hours
- Allergy or sensitivity to ASA or NSAIDs
- Patient on anticoagulation therapy
- Current active bleeding
- Hx of peptic ulcer disease or GI bleed
- Pregnant
- If asthmatic, no prior use of ASA or other NSAIDs
- CVA or TBI in the previous 24 hours
- Known renal impairment
- Active vomiting
- Unable to tolerate oral medication

**Ketorolac**
- NSAID or Ibuprofen use within previous 6 hours
- Allergy or sensitivity to ASA or NSAIDs
- Patient on anticoagulation therapy
- Current active bleeding
- Hx of peptic ulcer disease or GI bleed
- Pregnant
- If asthmatic, no prior use of ASA or other NSAIDs
- CVA or TBI in the previous 24 hours
- Known renal impairment

**Morphine**
- Allergy or sensitivity to Morphine
- SBP drops by one-third or more of its initial value after morphine is administered
### TREATMENT

**Consider acetaminophen:**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>960-1000 mg</td>
<td>1000 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**Consider ibuprofen:**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>400 mg</td>
<td>400 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**Consider ketorolac:**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM/IV</td>
<td>10-15 mg</td>
<td>15 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

**Consider morphine:**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max # doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC/IV</td>
<td>2-5 mg</td>
<td>5 mg</td>
<td>5 min</td>
<td>4</td>
</tr>
</tbody>
</table>
CLINICAL CONSIDERATIONS

Whenever possible, consider co-administration of acetaminophen and ibuprofen.

In patients with isolated hip or extremity trauma, ibuprofen and acetaminophen is preferred to ketorolac except where the patient is unable to tolerate oral medications.

If ketorolac is administered, neither acetaminophen nor ibuprofen should be administered.

Suspected renal colic patients should routinely be considered for ketorolac AND morphine.
HYPERKALEMIA MEDICAL DIRECTIVE

An Advanced Care Paramedic may provide the treatment prescribed in this Medical Directive if certified and authorized.

INDICATIONS

Suspected hyperkalemia in patients at high risk, including:

- currently on dialysis **OR**
- history of end-stage renal disease (ESRD) **OR**
- other reason to be highly suspicious of hyperkalemia (i.e. prolonged crush injury)

**AND**

one of the following clinical situations:

- Cardiac Arrest

**OR**

- pre-arrest (i.e. hypotension, altered level of consciousness, symptomatic bradycardia) with 12-lead ECG suggestive of hyperkalemia (i.e. wide and often bizarre QRS (>120 ms) with peaked T waves, loss of p waves and/or may have sine wave appearance)

CONDITIONS

<table>
<thead>
<tr>
<th>Calcium Gluconate 10%</th>
<th>Salbutamol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE:</strong> ≥18 years</td>
<td><strong>AGE:</strong> ≥18 years</td>
</tr>
<tr>
<td><strong>WEIGHT:</strong> N/A</td>
<td><strong>WEIGHT:</strong> N/A</td>
</tr>
<tr>
<td><strong>LOA:</strong> N/A</td>
<td><strong>LOA:</strong> N/A</td>
</tr>
<tr>
<td><strong>HR:</strong> N/A</td>
<td><strong>HR:</strong> N/A</td>
</tr>
<tr>
<td><strong>RR:</strong> N/A</td>
<td><strong>RR:</strong> N/A</td>
</tr>
<tr>
<td><strong>SBP:</strong> N/A</td>
<td><strong>SBP:</strong> N/A</td>
</tr>
<tr>
<td><strong>Other:</strong> N/A</td>
<td><strong>Other:</strong> N/A</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

**Calcium Gluconate 10%**
- Patients on Digoxin

**Salbutamol**
- Allergy or sensitivity to salbutamol

TREATMENT

**MANDATORY PROVINCIAL PATCH POINT:**
Patch to BHP for authorization to proceed with calcium gluconate and salbutamol therapies. Record ECG before and after treatment.

Consider **calcium gluconate 10%:**

<table>
<thead>
<tr>
<th>Route</th>
<th>IV/IO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>1 g (10 ml) over 2-3 minutes</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>1 g (10 ml)</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>30 minutes</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
</tr>
</tbody>
</table>

Consider **salbutamol** (this may not be possible in cardiac arrest):

<table>
<thead>
<tr>
<th>Route</th>
<th>MDI</th>
<th>Nebulized</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>1600 mcg* (16 puffs)</td>
<td>10 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>1600 mcg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>immediate</td>
<td>immediate</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

*1 puff=100 mcg*
CLINICAL CONSIDERATIONS

Whenever possible, both calcium gluconate and salbutamol should be given as the two medications have different modes of action.

If appropriate, refer to the Symptomatic Bradycardia, Tachydsrhythmia, or Cardiac Arrest Medical Directives for further management of these patients.

Sodium bicarbonate is not a very effective agent for hyperkalemia and so should not routinely be given.

Caution that calcium gluconate should only be administered in an IV/IO that is running well and that calcium gluconate and sodium bicarbonate should not be mixed or given in the same IV without flushing well.
TABLE OF CONTENTS

Intravenous and Fluid Therapy Medical Directive - AUXILIARY ................................................................. 3-1
Continuous Positive Airway Pressure (CPAP) Medical Directive - AUXILIARY ........................................... 3-4
Supraglottic Airway Medical Directive - AUXILIARY ................................................................................ 3-7
Nausea/Vomiting Medical Directive - AUXILIARY ..................................................................................... 3-9
Electronic Control Device Probe Removal Medical Directive - AUXILIARY .............................................. 3-11
Minor Abrasions Medical Directive - AUXILIARY - SPECIAL EVENT .......................................................... 3-13
Minor Allergic Reaction Medical Directive - AUXILIARY - SPECIAL EVENT ............................................. 3-15
Musculoskeletal Pain Medical Directive - AUXILIARY - SPECIAL EVENT .................................................. 3-17
Headache Medical Directive – AUXILIARY – SPECIAL EVENT ................................................................. 3-19
Home Dialysis Emergency Disconnect Medical Directive - AUXILIARY .................................................... 3-21
INTRAVENOUS AND FLUID THERAPY MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized according to the PCP Autonomous IV level.

INDICATIONS

Actual or potential need for intravenous medication OR fluid therapy

CONDITIONS

<table>
<thead>
<tr>
<th>IV</th>
<th>0.9% NaCl Fluid Bolus</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥2 years</td>
<td>AGE: ≥2 years</td>
</tr>
<tr>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: Hypotension</td>
</tr>
<tr>
<td>Other: N/A</td>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINdications

<table>
<thead>
<tr>
<th>IV</th>
<th>0.9% NaCl Fluid Bolus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected fracture proximal to the access site</td>
<td>Signs of fluid overload</td>
</tr>
</tbody>
</table>

TREATMENT

Consider IV cannulation
Consider **0.9% NaCl** maintenance infusion:

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥2 years to &lt;12 years</td>
<td>IV</td>
<td>15 ml/hr</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV</td>
<td>30-60 ml/hr</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**MANDATORY PROVINCIAL PATCH POINT:**

Patch to BHP for authorization to administer IV NaCl bolus to a patient ≥2 years to <12 years with suspected Diabetic Ketoacidosis (DKA)

Consider **0.9% NaCl fluid bolus**:

<table>
<thead>
<tr>
<th>Age</th>
<th>Route</th>
<th>Infusion</th>
<th>Infusion interval</th>
<th>Reassess every</th>
<th>Max. volume*</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥2 years to &lt;12 years</td>
<td>IV</td>
<td>20 ml/kg</td>
<td>Immediate</td>
<td>100 ml</td>
<td>20 ml/kg up to 2,000 ml</td>
</tr>
<tr>
<td>≥12 years</td>
<td>IV</td>
<td>20 ml/kg</td>
<td>Immediate</td>
<td>250 ml</td>
<td>2,000 ml</td>
</tr>
</tbody>
</table>

*The maximum volume of NaCl is lower for patients in cardiogenic shock*
CLINICAL CONSIDERATIONS

“PCP Assist IV” authorizes a PCP to cannulate a peripheral IV at the request and under the direct supervision of an ACP. The patient must require a peripheral IV in accordance with the indications listed in this Medical Directive. PCPs certified in PCP Assist IV are not authorized to administer IV fluid or medication therapy.

Microdrips and or volume control administration sets should be considered when IV access is indicated for patients less than 12 years of age.
CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Severe respiratory distress

AND

Signs and/or symptoms of acute pulmonary edema OR COPD

CONDITIONS

<table>
<thead>
<tr>
<th>CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE:</td>
</tr>
<tr>
<td>LOA:</td>
</tr>
<tr>
<td>HR:</td>
</tr>
<tr>
<td>RR:</td>
</tr>
<tr>
<td>SBP:</td>
</tr>
<tr>
<td>Other:</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

CPAP
Asthma exacerbation
Suspected pneumothorax
Unprotected or unstable airway
Major trauma or burns to the head or torso
Tracheostomy
Inability to sit upright
Unable to cooperate

TREATMENT

Consider **CPAP**:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Or equivalent flow rate of device as per BH direction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial setting</strong></td>
<td>5 cm H₂O</td>
<td></td>
</tr>
<tr>
<td><strong>Titration increment</strong></td>
<td>2.5 cm H₂O</td>
<td></td>
</tr>
<tr>
<td><strong>Titration interval</strong></td>
<td>5 min.</td>
<td></td>
</tr>
<tr>
<td><strong>Max. setting</strong></td>
<td>15 cm H₂O</td>
<td></td>
</tr>
</tbody>
</table>
Consider increasing \( \text{FiO}_2 \) (if available):

<table>
<thead>
<tr>
<th>( \text{Initial FiO}_2 )</th>
<th>50-100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{FiO}_2 ) increment (if available on device)</td>
<td>SpO(_2) &lt;92% despite treatment and/or 10cm H(_2)O pressure or equivalent flow rate of device as per BH direction</td>
</tr>
<tr>
<td>( \text{Max FiO}_2 )</td>
<td>100%</td>
</tr>
</tbody>
</table>

Confirm \textit{CPAP pressure by manometer} (if available)

**CLINICAL CONSIDERATIONS**

N/A
SUPRAGLOTTIC AIRWAY MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Need for ventilatory assistance OR airway control

AND

Other airway management is inadequate or ineffective

CONDITIONS

Supraglottic Airway

AGE: N/A
LOA: N/A
HR: N/A
RR: N/A
SBP: N/A
Other: patient must be in cardiac arrest

CONTRAINDICATIONS

Supraglottic Airway

Active vomiting
Inability to clear the airway
Airway edema
Stridor
Caustic ingestion
TREATMENT

Consider **supraglottic airway insertion**. The maximum number of attempts is 2.

Confirm **supraglottic airway placement**:

<table>
<thead>
<tr>
<th>Method</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Secondary</td>
</tr>
<tr>
<td>Auscultation</td>
<td>ETCO₂</td>
</tr>
<tr>
<td>Chest rise</td>
<td>Other</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

An attempt at supraglottic airway insertion is defined as the insertion of the supraglottic airway into the mouth.
NAUSEA / VOMITING MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Nausea OR vomiting

CONDITIONS

<table>
<thead>
<tr>
<th>Dimenhydrinate</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
</tr>
<tr>
<td>WEIGHT: ≥25 kg</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Dimenhydrinate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to dimenhydrinate or other antihistamines</td>
</tr>
<tr>
<td>Overdose on antihistamines or anticholinergics or tricyclic antidepressants</td>
</tr>
</tbody>
</table>
TREATMENT

Consider *dimenhydrinate*:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Route</th>
<th>Weight</th>
<th>Route</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥25 kg to &lt;50 kg</td>
<td>IV</td>
<td>IM</td>
<td>≥50 kg</td>
<td>IV</td>
<td>IM</td>
</tr>
<tr>
<td>Dose</td>
<td>25 mg</td>
<td>25 mg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>25 mg</td>
<td>25 mg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

IV administration of dimenhydrinate applies only to PCPs certified to the level of PCP Autonomous IV.

Prior to IV administration, dilute dimenhydrinate (concentration of 50 mg/1 ml) 1:9 with Normal Saline or sterile water. If given IM do not dilute.
ELECTRONIC CONTROL DEVICE PROBE REMOVAL MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Electronic Control Device probe(s) embedded in patient.

CONDITIONS

<table>
<thead>
<tr>
<th>Probe Removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

Probes removal

Probes embedded above the clavicles, in the nipple(s), or in the genital area.

TREATMENT

Consider probe removal
CLINICAL CONSIDERATIONS

Police may require preservation of the probe(s) for evidentiary purposes.

This directive is for removal of ECD only and in no way constitutes treat and release, normal principles of patient assessment and care apply.
MINOR ABRASIONS MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Minor abrasions

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

Topical Antibiotic

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>N/A</td>
</tr>
<tr>
<td>LOA</td>
<td>Unaltered</td>
</tr>
<tr>
<td>HR</td>
<td>N/A</td>
</tr>
<tr>
<td>RR</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP</td>
<td>N/A</td>
</tr>
<tr>
<td>Other</td>
<td>N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

Topical Antibiotic

Allergy or sensitivity to any of the components of the topical antibiotic
TREATMENT

Consider *topical antibiotic*

Consider *release from care*

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
MINOR ALLERGIC REACTION MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Signs consistent with minor allergic reaction

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

Diphenhydramine

AGE: ≥18 years
LOA: Unaltered
HR: WNL
RR: WNL
SBP: Normotension
Other: N/A
CONTRAINDICATIONS

Diphenhydramine
- Allergy or sensitivity to diphenhydramine
- Antihistamine or sedative use in previous 4 hours
- Signs or symptoms of moderate to severe allergic reaction
- Signs or symptoms of intoxication
- Wheezing

TREATMENT

Consider *diphenhydramine*:

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>PO</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td>50 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td>50 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Consider *release from care*

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
MUSCULOSKELETAL PAIN MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized.

INDICATIONS

Minor musculoskeletal pain

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

Acetaminophen

AGE: ≥18 years
LOA: Unaltered
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Acetaminophen

Acetaminophen use within previous 4 hours
Allergy or sensitivity to acetaminophen
Signs or symptoms of intoxication
TREATMENT

Consider *acetaminophen*:

<table>
<thead>
<tr>
<th>Route</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
<td>325-650 mg</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td>650 mg</td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **release from care**

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
HEADACHE MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Uncomplicated headache conforming to the patient’s usual pattern

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

<table>
<thead>
<tr>
<th>Acetaminophen</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Acetaminophen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen use within previous 4 hours</td>
</tr>
<tr>
<td>Allergy or sensitivity to acetaminophen</td>
</tr>
<tr>
<td>Signs or symptoms of intoxication</td>
</tr>
</tbody>
</table>
TREATMENT

Consider acetaminophen:

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PO</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose</th>
<th>325-650 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max. single dose</td>
<td>650 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider release from care

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
HOME DIALYSIS EMERGENCY DISCONNECT MEDICAL DIRECTIVE - AUXILIARY

A Primary Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Patient receiving home dialysis (hemo or peritoneal) and connected to dialysis machine

AND

Patient requires transport to the hospital

AND

Patient is unable to disconnect OR there is no family member or caregiver available or knowledgeable in dialysis disconnect

CONDITIONS

Home Dialysis Emergency Disconnect

AGE: N/A
LOA: N/A
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Home Dialysis Emergency Disconnect

N/A
TREATMENT

Consider *Home Dialysis Emergency Disconnect*

CLINICAL CONSIDERATIONS

Generally, emergency disconnect kit with materials and instructions can be found hanging from dialysis machine or nearby on the wall.

Ensure both the patient side and machine side of the connection are clamped before disconnecting and attaching end caps.
Appendix 4

Advanced Care Paramedic
Auxiliary Medical Directives
# TABLE OF CONTENTS

- Adult Intraosseous Medical Directive - AUXILIARY ................................................................. 4-1
- Central Venous Access Device Access Medical Directive - AUXILIARY .............................. 4-3
- Continuous Positive Airway Pressure (CPAP) Medical Directive - AUXILIARY ..................... 4-5
- Supraglottic Airway Medical Directive - AUXILIARY ............................................................... 4-8
- Cricothyrotomy Medical Directive - AUXILIARY ............................................................... 4-10
- Nausea/Vomiting Medical Directive - AUXILIARY ............................................................... 4-12
- Combative Patient Medical Directive - AUXILIARY .......................................................... 4-14
- Procedural Sedation Medical Directive - AUXILIARY ..................................................... 4-16
- Electronic Control Device Probe Removal Medical Directive - AUXILIARY ....................... 4-18
- Minor Abrasions Medical Directive – AUXILIARY – SPECIAL EVENT ................................. 4-20
- Minor Allergic Reaction Medical Directive – AUXILIARY – SPECIAL EVENT ..................... 4-22
- Musculoskeletal Pain Medical Directive – AUXILIARY – SPECIAL EVENT ....................... 4-24
- Headache Medical Directive – AUXILIARY – SPECIAL EVENT ........................................... 4-26
- Nasotracheal Intubation Medical Directive – AUXILIARY .................................................... 4-28
- Home Dialysis Emergency Disconnect Medical Directive - AUXILIARY ......................... 4-31
ADULT INTRAOSSEOUS MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Actual or potential need for intravenous medication OR fluid therapy

AND

IV access is unobtainable

AND

Cardiac arrest OR near arrest state

CONDITIONS

IO
AGE: ≥12 years
LOA: N/A
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATION

IO
Fracture or crush injuries or suspected or known replacement / prosthesis proximal to the access site.
TREATMENT

Consider IO access

CLINICAL CONSIDERATIONS

N/A
**CENTRAL VENOUS ACCESS DEVICE ACCESS MEDICAL DIRECTIVE - AUXILIARY**

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

**INDICATIONS**

Actual or potential need for intravenous medication **OR** fluid therapy

**AND**

IV access is unobtainable

**AND**

Cardiac arrest **OR** near arrest state

**CONDITIONS**

<table>
<thead>
<tr>
<th>CVAD Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
</tr>
<tr>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Patient has a pre-existing, accessible central venous catheter in place</td>
</tr>
</tbody>
</table>

**CONTRAINDICATIONS**

<table>
<thead>
<tr>
<th>CVAD Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
</tr>
</tbody>
</table>
TREATMENT

Consider *CVAD access*

CLINICAL CONSIDERATIONS

N/A
CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Severe respiratory distress

AND

Signs and/or symptoms of acute pulmonary edema OR COPD

CONDITIONS

CPAP

| AGE: | ≥18 years |
| LOA: | N/A |
| HR:  | N/A |
| RR:  | Tachypnea |
| SBP: | Normotension |
| Other: | SpO₂ <90% or accessory muscle use |
CONTRAINDICATIONS

CPAP
- Asthma exacerbation
- Suspected pneumothorax
- Unprotected or unstable airway
- Major trauma or burns to the head or torso
- Tracheostomy
- Inability to sit upright
- Unable to cooperate

TREATMENT

Consider **CPAP**:

<table>
<thead>
<tr>
<th><strong>Initial setting</strong></th>
<th>5 cm H₂O</th>
<th>Or equivalent flow rate of device as per BH direction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Titration increment</strong></td>
<td>2.5 cm H₂O</td>
<td>Or equivalent flow rate of device as per BH direction</td>
</tr>
<tr>
<td><strong>Titration interval</strong></td>
<td>5 min.</td>
<td></td>
</tr>
<tr>
<td><strong>Max. setting</strong></td>
<td>15 cm H₂O</td>
<td>Or equivalent flow rate of device as per BH direction</td>
</tr>
</tbody>
</table>
Consider increasing $FiO_2$ (if available):

<table>
<thead>
<tr>
<th>$FiO_2$ increment (if available on device)</th>
<th>SpO$_2$ &lt;92% despite treatment and/or 10cm H$_2$O pressure or equivalent flow rate of device as per BH direction</th>
</tr>
</thead>
<tbody>
<tr>
<td>$FiO_2$ increment (if available on device)</td>
<td>$FiO_2$ increment (if available on device)</td>
</tr>
<tr>
<td>50-100%</td>
<td>Max $FiO_2$ 100%</td>
</tr>
</tbody>
</table>

Confirm **CPAP pressure by manometer** (if available)

**CLINICAL CONSIDERATIONS**

N/A
SUPRAGLOTTIC AIRWAY MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Need for ventilatory assistance OR airway control
AND
Other airway management is inadequate OR ineffective OR unsuccessful

CONDITIONS

Supraglottic Airway
AGE: N/A
LOA: GCS = 3
HR: N/A
RR: N/A
SBP: N/A
Other: Absent gag reflex

CONTRAINDICATIONS

Supraglottic Airway
Active vomiting
Inability to clear the airway
Airway edema
Stridor
Caustic ingestion
TREATMENT

Consider *supraglottic airway insertion*. The maximum number of attempts is 2.

Confirm *supraglottic airway placement*:

<table>
<thead>
<tr>
<th>Method</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Secondary</td>
</tr>
<tr>
<td>Auscultation</td>
<td>ETCO₂</td>
</tr>
<tr>
<td>Chest rise</td>
<td>Other</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

An attempt at supraglottic airway insertion is defined as the insertion of the supraglottic airway into the mouth. The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2).
CRICOXYTHROTONY MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Need for advanced airway management
AND
Intubation AND supraglottic airway (if available) insertion unsuccessful or contraindicated
AND
Unable to ventilate

CONDITIONS

<table>
<thead>
<tr>
<th>Cricothyrotomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥12 years</td>
</tr>
<tr>
<td>LOA: Altered</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Cricothyrotomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected fractured larynx</td>
</tr>
<tr>
<td>Inability to landmark</td>
</tr>
</tbody>
</table>
TREATMENT

MANDATORY PROVINCIAL PATCH POINT:

Patch to BHP for authorization to perform cricothyrotomy

Consider cricothyrotomy

Confirm cricothyrotomy: tube placement

<table>
<thead>
<tr>
<th>Method</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Secondary</td>
</tr>
<tr>
<td>Auscultation</td>
<td>ETCO₂</td>
</tr>
<tr>
<td>Chest rise</td>
<td>Other</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

At least two primary and one secondary Cricothyrotomy tube placement confirmation methods must be used.

If the patient has a pulse, an ETCO₂ device must be used (quantitative or qualitative) for cricothyrotomy tube placement confirmation.

Additional secondary Cricothyrotomy tube placement confirmation devices may be authorized by the local medical director.

Cricothyrotomy tube placement must be reconfirmed immediately after every patient movement.
NAUSEA/VOMITING MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Nausea OR vomiting

CONDITIONS

Dimenhydrinate
AGE: N/A
LOA: Unaltered
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Dimenhydrinate
Allergy or sensitivity to dimenhydrinate or other antihistamines
Overdose on antihistamines or anticholinergics or tricyclic antidepressants
TREATMENT

Consider *dimenhydrinate*:

<table>
<thead>
<tr>
<th>Weight</th>
<th>Route</th>
<th>Route</th>
<th>Weight</th>
<th>Route</th>
<th>Route</th>
<th>Weight</th>
<th>Route</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV</td>
<td>IM</td>
<td>≥25 kg to &lt;50 kg</td>
<td>IV</td>
<td>IM</td>
<td>≥50 kg</td>
<td>IV</td>
<td>IM</td>
</tr>
<tr>
<td>Weight &lt;25 kg</td>
<td>Patch</td>
<td>Patch</td>
<td>25 mg</td>
<td>25 mg</td>
<td>25 mg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>N/A</td>
<td>N/A</td>
<td>25 mg</td>
<td>25 mg</td>
<td>25 mg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>N/A</td>
<td>N/A</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

Prior to IV administration, dilute dimenhydrinate (concentration of 50 mg/1 ml) 1:9 with Normal Saline or sterile water. If given IM do not dilute.
COMBATIVE PATIENT MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS
Combative patient

CONDITIONS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td></td>
</tr>
<tr>
<td>AGE:</td>
<td>≥18 years</td>
</tr>
<tr>
<td>LOA:</td>
<td>N/A</td>
</tr>
<tr>
<td>HR:</td>
<td>N/A</td>
</tr>
<tr>
<td>RR:</td>
<td>N/A</td>
</tr>
<tr>
<td>SBP:</td>
<td>Normotension</td>
</tr>
<tr>
<td>Other:</td>
<td>No reversible causes (i.e. hypoglycemia, hypoxia, hypotension)</td>
</tr>
</tbody>
</table>

CONTRAINDICATIONS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td></td>
</tr>
<tr>
<td>Allergy or sensitivity to midazolam</td>
<td></td>
</tr>
</tbody>
</table>
TREATMENT

MANDATORY PROVINCIAL PATCH POINT:
Patch to BHP for authorization to proceed with midazolam if unable to assess the patient for normotension or reversible causes.

Consider **midazolam**:

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV</td>
<td>IM</td>
</tr>
<tr>
<td>Dose</td>
<td>2.5-5 mg</td>
<td>2.5-5 mg</td>
</tr>
<tr>
<td>Max. single dose</td>
<td>5 mg</td>
<td>5 mg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>5 min.</td>
<td>5 min.</td>
</tr>
<tr>
<td>Max. total dose</td>
<td>10 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Max. # doses</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

CLINICAL CONSIDERATIONS

N/A
PROCEDURAL SEDATION MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Post-intubation OR transcutaneous pacing

CONDITIONS

<table>
<thead>
<tr>
<th>Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: ≥8/min*</td>
</tr>
<tr>
<td>SBP: Normotension</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

*Non-intubated patients only

CONTRAINDICATIONS

<table>
<thead>
<tr>
<th>Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy or sensitivity to midazolam</td>
</tr>
</tbody>
</table>
Consider *midazolam*:

<table>
<thead>
<tr>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
</tr>
</tbody>
</table>
| **Dose** | 2.5-5 mg  
| **Max. single dose** | 5 mg  
| **Dosing interval** | 5 min.  
| **Max. total dose** | 10 mg  
| **Max. # doses** | 2  

**CLINICAL CONSIDERATIONS**

N/A
ELECTRONIC CONTROL DEVICE PROBE REMOVAL MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Electronic Control Device probe(s) embedded in patient.

CONDITIONS

Probe Removal
AGE: ≥18 years
LOA: Unaltered
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Probe removal
Probe embedded above the clavicles, in the nipple(s), or in the genital area

TREATMENT

Consider probe removal
CLINICAL CONSIDERATIONS

Police may require preservation of the probe(s) for evidentiary purposes.

This directive is for removal of ECD only and in no way constitutes treat and release, normal principles of patient assessment and care apply.
MINOR ABRASIONS MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Minor abrasions
AND
Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

Topical Antibiotic
AGE: N/A
LOA: Unaltered
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Topical Antibiotic
Allergy or sensitivity to topical antibiotics

TREATMENT

Consider topica]l antibiotic
Consider release from care

**CLINICAL CONSIDERATIONS**

Advise patient that if the problem persists or worsens that they should seek further medical attention.
MINOR ALLERGIC REACTION MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Signs consistent with minor allergic reaction

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

<table>
<thead>
<tr>
<th>Diphenhydramine</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: ≥18 years</td>
</tr>
<tr>
<td>LOA: Unaltered</td>
</tr>
<tr>
<td>HR: WNL</td>
</tr>
<tr>
<td>RR: WNL</td>
</tr>
<tr>
<td>SBP: Normotension</td>
</tr>
<tr>
<td>Other: N/A</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

Diphenhydramine
Allergy or sensitivity to diphenhydramine
Antihistamine or sedative use in previous 4 hours
Signs or symptoms of moderate to severe allergic reaction
Signs or symptoms of intoxication
Wheezing

TREATMENT

Consider diphenhydramine:

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>50 mg</td>
<td>50 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider release from care

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
MUSCULOSKELETAL PAIN MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary medical directive if certified and authorized.

INDICATIONS

Minor musculoskeletal pain

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

**Acetaminophen**

AGE: ≥18 years

LOA: Unaltered

HR: N/A

RR: N/A

SBP: N/A

Other: N/A

CONTRAINDICATIONS

**Acetaminophen**

Acetaminophen use within previous 4 hours

Allergy or sensitivity to acetaminophen

Signs or symptoms of intoxication
TREATMENT

Consider *acetaminophen*:

<table>
<thead>
<tr>
<th>Route</th>
<th>PO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
<td>325-650 mg</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td>650 mg</td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>1</td>
</tr>
</tbody>
</table>

Consider **release from care**

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
HEADACHE MEDICAL DIRECTIVE – AUXILIARY – SPECIAL EVENT

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Uncomplicated headache conforming to the patient’s usual pattern

AND

Special event: a preplanned gathering with potentially large numbers and the Special Event Medical Directives have been preauthorized for use by the Medical Director

CONDITIONS

Acetaminophen

AGE: ≥18 years
LOA: Unaltered
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Acetaminophen

Acetaminophen use within the previous 4 hours
Allergy or sensitivity to acetaminophen
Signs or symptoms of intoxication
TREATMENT

Consider acetaminophen:

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Max. single dose</th>
<th>Dosing interval</th>
<th>Max. # of doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>325-650 mg</td>
<td>650 mg</td>
<td>N/A</td>
<td>1</td>
</tr>
</tbody>
</table>

Consider release from care

CLINICAL CONSIDERATIONS

Advise patient that if the problem persists or worsens that they should seek further medical attention.
NASOTRACHEAL INTUBATION MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Need for ventilatory assistance **OR** airway control

AND

Other airway management is inadequate or ineffective

CONDITIONS

<table>
<thead>
<tr>
<th>Xylometazoline</th>
<th>Lidocaine Spray</th>
<th>Nasotracheal Intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: N/A</td>
<td>AGE: N/A</td>
<td>AGE: ≥8 years</td>
</tr>
<tr>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
<td>LOA: N/A</td>
</tr>
<tr>
<td>HR: N/A</td>
<td>HR: N/A</td>
<td>HR: N/A</td>
</tr>
<tr>
<td>RR: N/A</td>
<td>RR: N/A</td>
<td>RR: N/A</td>
</tr>
<tr>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
<td>SBP: N/A</td>
</tr>
<tr>
<td>Other: Nasotracheal Intubation</td>
<td>Other: Nasotracheal Intubation</td>
<td>Other: Spontaneous Breathing</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS

**Xylometazoline**
- Allergy or sensitivity to xylometazoline

**Lidocaine**
- Allergy or sensitivity to lidocaine
- Unresponsive patient

**Nasotracheal Intubation**
- Age <50 years AND current episode of asthma exacerbation AND not in or near cardiac arrest.
- Suspected basal skull fracture or mid-face fracture
- Uncontrolled epistaxis
- Anticoagulant therapy (excluding ASA)
- Bleeding disorders

TREATMENT

Consider *xylometazoline 0.1% spray*: for nasotracheal intubation

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
<td>2 sprays/nare</td>
</tr>
<tr>
<td><strong>Max. single dose</strong></td>
<td>2 sprays/nare</td>
</tr>
<tr>
<td><strong>Dosing interval</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Max. # of doses</strong></td>
<td>1</td>
</tr>
</tbody>
</table>
Consider topical **lidocaine** spray (to the nares and/or hypopharynx) for “awake” nasotracheal intubation:

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPICAL</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose</th>
<th>10 mg/spray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max. dose</td>
<td>5mg/kg</td>
</tr>
<tr>
<td>Dosing interval</td>
<td>N/A</td>
</tr>
<tr>
<td>Max. # of doses</td>
<td>20 sprays</td>
</tr>
</tbody>
</table>

Consider *nasotracheal intubation*. The maximum number of intubation attempts is 2.

Confirm *nasotracheal tube placement*:

<table>
<thead>
<tr>
<th>Method</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td><strong>Secondary</strong></td>
</tr>
<tr>
<td>Auscultation</td>
<td>ETCO₂</td>
</tr>
<tr>
<td>Chest rise</td>
<td>EDD</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>

**CLINICAL CONSIDERATIONS**

An intubation attempt is defined as insertion of the nasotracheal tube into a nare.

The maximum number of supraglottic airway attempts is two (2) and the maximum number of intubation attempts is two (2).

The two primary and at least one secondary nasotracheal placement confirmation methods must be used.

An ETCO₂ device (quantitative or qualitative) must be used for ETT placement confirmation.

Additional secondary ETT placement confirmation devices may be authorized by the local medical director.

ETT placement must be reconfirmed immediately after every patient movement.
HOME DIALYSIS EMERGENCY DISCONNECT MEDICAL DIRECTIVE - AUXILIARY

An Advanced Care Paramedic may provide the treatment prescribed in this auxiliary Medical Directive if certified and authorized.

INDICATIONS

Patient receiving home dialysis (hemo or peritoneal) and connected to dialysis machine

AND

Patient requires transport to the hospital

AND

Patient is unable to disconnect OR there is no family member or caregiver available or knowledgeable in dialysis disconnect

CONDITIONS

Home Dialysis Emergency Disconnect

AGE: N/A
LOA: N/A
HR: N/A
RR: N/A
SBP: N/A
Other: N/A

CONTRAINDICATIONS

Home Dialysis Emergency Disconnect

N/A
TREATMENT

Consider *Home Dialysis Emergency Disconnect*

CLINICAL CONSIDERATIONS

Generally, emergency disconnect kit with materials and instructions can be found hanging from dialysis machine or nearby on the wall.

Ensure both the patient side and machine side of the connection are clamped before disconnecting and attaching end caps.
Appendix 5

Chemical Exposure
Medical Directives
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5-1</td>
</tr>
<tr>
<td>Hydrofluoric Acid Exposure Medical Directive</td>
<td>5-2</td>
</tr>
<tr>
<td>Administration of Atropine, either Pralidoxime Chloride (2 PAM) or Obidoxime and Diazepam for Nerve Agent Exposure Medical Directive</td>
<td>5-4</td>
</tr>
<tr>
<td>Pediatric Administration of Atropine, either Pralidoxime Chloride (2 PAM) or Obidoxime and Diazepam for Nerve Agent Exposure Medical Directive</td>
<td>5-6</td>
</tr>
<tr>
<td>Administration of Antidotes for Cyanide Exposure Medical Directive</td>
<td>5-8</td>
</tr>
<tr>
<td>Symptomatic Riot Agent Exposure Medical Directive</td>
<td>5-9</td>
</tr>
</tbody>
</table>
CHEMICAL EXPOSURE MEDICAL DIRECTIVES

INTRODUCTION

The following Medical Directives have been developed for use when chemical exposure to the listed agent is suspected. These Medical Directives may only be used by paramedics who have received special training in treating patients with chemical exposures. This is usually a comprehensive program that includes personal protection and training in CBRNE (Chemical, Biologic, Radiological, Nuclear and Explosive) events.
HYDROFLUORIC ACID EXPOSURE MEDICAL DIRECTIVE

When the listed indication and condition exist, a paramedic is authorized to administer Calcium Gluconate and/or topical anaesthetic eye drops according to the following protocol. The paramedic will comply with local BHP patching protocols.

INDICATIONS:

Patient was exposed to vapour, and/or liquid hydrofluoric acid.

CONDITIONS:

Patient is exhibiting signs and symptoms of hydrofluoric acid poisoning.

CONTRAINDICATIONS:

Topical anaesthetic eye drops (see Procedure, point #6a) are contraindicated if the patient is allergic to anaesthetics.

PROCEDURE:

1. Don appropriate PPE.
2. Remove patient from further hydrofluoric acid exposure, remove contaminated clothing, jewellery, etc.
3. Decontaminate if not already decontaminated.
4. Assess vital signs; apply cardiac monitor and high flow oxygen.
5. Inhalation:
   a) Ensure airway patency and breathing.
   b) For dyspnea see Bronchoconstriction Medical Directive.
   c) If airway pain (suspected inhalation injury), consider delivering a nebulized Calcium Gluconate 2.5% solution (1 ml 10% Calcium Gluconate and 3 ml sterile normal saline) with high flow oxygen.
6. **Eye Contact:**
   For eye discomfort, irrigate thoroughly with copious amounts of normal saline.
   a) Remove contact lenses.
   b) Administer 2 drops of topical anaesthetic eye drops in each eye, repeat every 10 minutes as needed.
   c) Monitor the patient for 20 minutes after the last dose.

7. **Skin Contact:**
   a) Irrigate thoroughly with copious amounts of saline for 1 minute if not already done.
   b) Massage Calcium Gluconate 2.5% Gel (if available) liberally into the burn area and continue applying during transport if pain persists.

**NOTES:**

1. Transport to hospital as soon as possible.
2. Latex gloves are not sufficient. Use Neoprene or Nitrile gloves.
ADMINISTRATION OF ATROPINE, EITHER PRALIDOXIME CHLORIDE (2 PAM) OR OBIDOXIME AND DIAZEPAM FOR NERVE AGENT EXPOSURE MEDICAL DIRECTIVE

When the listed indication and conditions exist, a paramedic is authorized to administer Atropine, either Pralidoxime or Obidoxime and Diazepam to a victim of nerve agent (or organophosphate) exposure. The paramedic will comply with local BHP patching protocols.

INDICATIONS:

Patient was exposed to known or suspected nerve agent.

CONDITIONS:

1. Adult (≥40 kg)
2. The patient is exhibiting signs and symptoms of a cholinergic crisis.

PROCEDURE:

Mild Exposure:
Signs: anxiety about being exposed, may see miosis, rhinorrhea.

1. Remove patient from area of exposure.
2. Remove all contaminated clothing.

Moderate Exposure:
Signs: (ANY ONE OF) vomiting, diarrhea, bronchospasm or bronchial secretions, shortness of breath, any known liquid exposure.

☐ Administer:

1. One (1) Atropine 2mg IM or autoinjector. Repeat Atropine 2mg IV/IM every 5 minutes as needed until symptoms improve.
2. One (1) Pralidoxime 600mg IM or autoinjector OR Obidoxime 150mg IM or autoinjector.
3. One (1) Diazepam 10mg IM or autoinjector.
**Severe Exposure:**

Signs: Signs of moderate exposure and (ANY ONE OF) Decreased LOC, paralysis, seizures, apnea.

- Administer:
  1. Three (3) doses Atropine 2mg IV/IM or autoinjectors. If bronchial secretions persist, continue Atropine 2mg IV/IM every 5 minutes as needed until secretions clear.
  2. Three (3) doses Pralidoxime 600mg IM or autoinjectors OR three (3) Obidoxime 150mg IM or autoinjectors.
  3. One (1) Diazepam 10mg IM or autoinjector.

**NOTES:**

1. Patients receiving treatment should also receive oxygen and be on a cardiac monitor if available.
2. Only Advanced Care Paramedics may administer intravenous medications.
3. ABC’s must also be secured as appropriate in an MCI/contaminated environment. Atropine should be administered prior to airway interventions if secretions are copious.
4. Decontamination procedures must be integrated with antidote administration.
5. Personal Protective Equipment must be worn at all times.
6. Drugs may be given IV but do not delay IM administration if IV access is not already established.
PEDIATRIC ADMINISTRATION OF ATROPINE, EITHER PRA Lidoxime CHLORIDE (2 PAM) OR OBIDOXIME AND DIAZEPAM FOR NERVE AGENT EXPOSURE
MEDICAL DIRECTIVE

When the listed indication and conditions exist, a paramedic is authorized to administer Atropine, either Pralidoxime or Obidoxime and Diazepam to a victim of nerve agent (or organophosphate) exposure. The paramedic will comply with local BHP patching protocols.

INDICATIONS:

Patient was exposed to known or suspected nerve agent.

CONDITIONS:

1. <40 kg
2. The patient is exhibiting signs and symptoms of a cholinergic crisis.

PROCEDURE:

**Mild Exposure:**

Signs: anxiety about being exposed, may see miosis, rhinorrhea.

1. Remove patient from area of exposure.
2. Remove all contaminated clothing.

**Moderate/Severe Exposure:**

Signs: (ANY ONE OF) vomiting, diarrhea, bronchospasm or bronchial secretions, shortness of breath, decreased LOC, paralysis, seizures, apnea, any known liquid exposure.

- Administer:
  - For patients <10kg:
    1. Atropine 0.5 mg IM, repeat IV/IM every 5 minutes as needed until symptoms improve.
    2. Diazepam 2mg IV/IM.
3. Pralidoxime 15mg/Kg IV/IM every 1 hour maximum 600mg/single dose, total maximum dose 1200mg
   OR Obidoxime 8mg/Kg maximum 320mg total dose.

   For patients from 10kg to 39kg:
   1. Atropine 1 mg IM, repeat IV/IM every 5 minutes as needed until symptoms improve.
   2. Diazepam 0.2 mg/kg IV/IM.
   3. Pralidoxime 15mg/Kg IV/IM every 1 hour maximum 600mg/single dose, total maximum dose
      1200mg OR Obidoxime 8mg/Kg maximum 320mg total dose.

**NOTES:**

1. Patients receiving treatment should also receive oxygen and be on a cardiac monitor if available.
2. Only Advanced Care Paramedics may administer intravenous medications.
3. ABC’s must also be secured as appropriate in an MCI/contaminated environment. Atropine should be
   administered prior to airway interventions if secretions are copious.
4. Decontamination procedures must be integrated with antidote administration.
5. Personal Protective Equipment must be worn at all times.
6. Drugs may given IV but do not delay IM administration if IV access is not already established.
ADMINISTRATION OF ANTIDOTES FOR CYANIDE EXPOSURE MEDICAL DIRECTIVE

When the listed indication and condition exist, a paramedic is authorized to administer antidotes to victims of Cyanide exposure according to the following protocol. The paramedic will comply with local BHP patching protocols.

INDICATIONS:

Patient was exposed to vapour, liquid or solid, suspected to contain cyanide.

CONDITIONS:

Patient is exhibiting signs and symptoms of cyanide poisoning.

PROCEDURE:

1. Remove patient from further exposure and remove clothes.
2. Assess vital signs, GCS.
3. Ensure airway, administer oxygen and apply cardiac and oxygen saturation monitors as possible.
4. If GCS 15 and patient is asymptomatic, decontaminate and transport to hospital.
5. If GCS <15 administer:
   a) Sodium Thiosulfate 12.5 gm (50 ml of 25% solution) IV
      (Pediatric dose = 1.65 ml/kg to max 50 ml).
      OR
   b) CYANOKIT (hydroxocobalamin) 5.0 g by rapid IV infusion over 30 minutes
      (Pediatric dose = 70 mg/kg)
6. Initiate treatment and continue while transport to hospital.
SYMPTOMATIC RIOT AGENT EXPOSURE MEDICAL DIRECTIVE

When the listed indication and condition exist, a paramedic is authorized to administer therapy to victims of Riot Agent exposure according to the following protocol. The paramedic will comply with local BHP patching protocols.

INDICATIONS:

Exposure to a known or suspected riot agent.

CONDITIONS:

Signs and symptoms of riot agent exposure.

CONTRAINDICATIONS:

Topical anaesthetic eye drops (see Procedure, point #5a) are contraindicated if the patient is allergic to anaesthetics.

PROCEDURE:

1. Remove patient from further exposure, and decontaminate.
2. Assess vital signs, with careful focus on bronchoconstriction.
3. Assess visual acuity by the ability to see light and count fingers at 1 foot. Consider removing contact lenses.
4. For dyspnea see Bronchoconstriction Medical Directive.
5. For eye discomfort, irrigate thoroughly with copious amounts of normal saline.
   a) Administer 2 drops of topical anaesthetic eye drops in each eye, repeat every 10 minutes as needed.
   b) Monitor the patient for 20 minutes after the last dose.
NOTES:

1. If a patient is experiencing significant respiratory distress or eye irritation, immediately advise the patient of the need for transport to hospital. Transport should be initiated as soon as possible.

2. MDIs are intended for single patient use only. If an MDI is used to treat more than one patient, cross contamination may occur regardless of whether or not an aerochamber or spacer is used. The MDI should be safely discarded once the patient has completed treatment.

3. The eye drop bottle is designed for multiple patient use. Do not allow the bottle’s administration nozzle to make contact with the patient. If the administration nozzle does make contact with the patient, the bottle is considered contaminated and must be discarded appropriately.

4. Under no circumstances should the MDI or eye drop bottle be given to a patient.

5. Advise patient to refrain from rubbing eyes, whether or not anaesthetic drops are used.

6. Have the patient remove their contact lenses. Help if necessary.

7. If a patient with dyspnea or eye irritation caused by a riot control agent refuses EMS transport to hospital, advise:

   CONTINUED EXPOSURE MAY LEAD TO FURTHER PROBLEMS. RELIEF FROM TREATMENT SO FAR MAY BE TEMPORARY. IF PROBLEMS RECUR OR PERSIST, CONSULT A PHYSICIAN AS SOON AS POSSIBLE.
# TABLE OF CONTENTS

- **Preamble** .............................................................................................................................................................. 6-1
- **Definitions** ............................................................................................................................................................ 6-1
- **Processes** ............................................................................................................................................................. 6-4
- **New Certification** .................................................................................................................................................. 6-6
- **Cross Certification** ............................................................................................................................................... 6-7
- **Maintenance of Certification** ............................................................................................................................. 6-7
- **Paramedic Practice Review Committee (PPRC)** ................................................................................................. 6-8
- **Appendix A - Paramedic Practice Review Committee Letter** ........................................................................... 6-10
Certification Standard

Preamble:
All Paramedics shall obtain and maintain the qualifications required by the Ambulance Act. This document sets out the requirements and processes related to Certification.

DEFINITIONS
Terms defined in the Ambulance Act and Ontario Regulation 257/00 shall have the same meaning in this Certification Standard and the following terms have the following meanings:

“Authorization” means written approval to perform Controlled Acts and other advanced medical procedures requiring medical oversight of a Medical Director;

“Business Day” means any working day, Monday to Friday inclusive, excluding statutory and other holidays, namely: New Year’s Day; Family Day; Good Friday; Easter Monday; Victoria Day; Canada Day; Civic Holiday; Labour Day; Thanksgiving Day; Remembrance Day; Christmas Day; Boxing Day and any other day on which the Province has elected to be closed for business;

“Certification” means the process by which Paramedics receive Authorization from a Medical Director to perform Controlled Acts and other advanced medical procedures in accordance with the ALS PCS;

“Continuing Medical Education (CME)” means a medical education program and confirmation of its successful completion as approved by the Regional Base Hospital Program (RBHP);

“Consolidation” means the process by which a condition is placed on a Paramedic’s Certification restricting his or her practice to working with another Paramedic with the same or higher level of qualification (i.e. Certification);

“Controlled Act” means a Controlled Act as set out in subsection 27(2) of the Regulated Health Professions Act, 1991;

“Critical Omission or Commission” means the performance of a Controlled Act or other advanced medical procedure listed in the ALS PCS that a Paramedic is not authorized to perform; or an action or lack of action, including the performance of a Controlled Act or other advanced medical procedure listed in the ALS PCS, by the Paramedic that
has negatively affected or has the potential to negatively affect patient morbidity or mortality, with a potentially life, limb or function threatening outcome;

“Deactivation”
means the temporary revocation, by the Medical Director, of a Paramedic’s Certification;

“Decertification”
means the revocation, by the Medical Director, of a Paramedic’s Certification;

“Director”
means a person who holds that position within the Emergency Health Services Branch (EHSB) of the Ministry of Health and Long-Term Care (MOHLTC);

“Employer”
means an ambulance service operator certified to provide ambulance services as defined in the Ambulance Act;

“Major Omission or Commission”
means an action or lack of action, including the performance of a Controlled Act or other advanced medical procedure listed in the ALS PCS, by the Paramedic that has negatively affected or has the potential to negatively affect patient morbidity without a potentially life, limb or function threatening outcome;

“Medical Director”
means a physician designated by a Regional Base Hospital as the Medical Director of the RBHP;

“Minor Omission or Commission”
means an action or lack of action, including the performance of a Controlled Act or other advanced medical procedure listed in the ALS PCS, by the Paramedic that may have negatively affected patient care in a way that would delay care to the patient or lengthen the patient’s recovery period, but has not negatively affected patient morbidity;

“Ontario Base Hospital Group (OBHG) Executive”
means a provincial body comprised of representatives from RBHPs as defined in the Terms of Reference for OBHG Executive and approved by the MOHLTC;

“Paramedic”
means a paramedic as defined in subsection 1(1) of the Ambulance Act, and for purposes of this Standard a reference to the term includes a person who is seeking Certification as a Paramedic, where applicable;
“Paramedic Practice Review Committee (PPRC)”
is a committee that performs an independent, external advisory role, providing information and expert opinion to the Medical Director on issues related to Paramedic practice when the Medical Director is considering Decertification of a Paramedic;

“Patient Care Concern”
means a Critical Omission or Commission, Major Omission or Commission, or Minor Omission or Commission;

“Reactivation”
means the reinstatement of a Paramedic’s Certification after a period of Deactivation;

“Regional Base Hospital (RBH)”
means a base hospital as defined in subsection 1(1) of the Ambulance Act, and provides an RBHP pursuant to an agreement entered into with the MOHLTC;

“Regional Base Hospital Program (RBHP)”
means a base hospital program as defined in subsection 1(1) of the Ambulance Act;

“Remediation”
means a customized plan by the RBHP to address a Patient Care Concern or to address any concerns identified during Certification, including a failure to meet a requirement for the maintenance of Certification;

“Senior Field Manager”
means a person who holds that position within the EHSB of the MOHLTC, and for the purposes of this Standard a reference to the term means the relevant Senior Field Manager responsible for the applicable RBHP.
**PROCESSES**

**Certification**

A Medical Director may certify a Paramedic to perform Controlled Acts and other advanced medical procedures listed in the ALS PCS. A Medical Director may stipulate other requirements relating to Paramedic Certification. The Medical Director shall communicate such requirements to the Paramedic and the Employer in writing. The Medical Director shall notify the Paramedic and Employer within three (3) Business Days of the decision with respect to Certification as to whether the Paramedic was successful or not in attaining his or her Certification.

**Consolidation**

The Medical Director shall require Consolidation on all new Certifications\(^1\). A Medical Director may require Consolidation with respect to a Paramedic’s Certification where the Paramedic is returning to practice, a Patient Care Concern has been identified in respect of the Paramedic, or as identified in the Paramedic’s customized plan for Remediation. Consolidation provides for the opportunity to acquire more skills and confidence while ensuring that a support mechanism is in place for the Paramedic. The Medical Director shall determine the requirements for the Consolidation, which include the presence of another Paramedic, the level of qualification of that other Paramedic, and the restrictions of the Paramedic’s practice in relation to the presence of that other Paramedic. The Medical Director, in consultation with the Employer, shall determine the duration for the Consolidation. However, the duration for Consolidation on all new Certifications shall be a minimum of 36 hours for a PCP and a minimum of 168 hours for an ACP or CCP. The Medical Director shall provide notice of Consolidation and the requirements thereof in writing to the Paramedic and Employer within two (2) Business Days. Any changes to the Consolidation by the Medical Director shall be communicated to the Paramedic and Employer immediately and any changes to the requirements thereof shall be provided in writing as soon as possible.

**Responding to a Patient Care Concern**

The RBHP shall assess all matters regarding patient care to determine whether or not there is a Patient Care Concern and the Employer shall assist where required. Where a matter regarding patient care is identified by the Employer that may be a Patient Care Concern, the Employer shall notify the RBHP as soon as possible.

Where the Patient Care Concern is a Minor Omission or Commission the RBHP shall notify the Paramedic and Employer by aggregate reports provided semi-annually. Where the Patient Care Concern is a Major Omission or Commission, a Critical Omission or Commission, or a repetition of Minor Omissions or Commissions the RBHP shall immediately notify the Paramedic and Employer of the Patient Care Concern and provide notice in writing as soon as possible. The notice in writing shall indicate that the Patient Care Concern is being considered to determine whether the Paramedic will be subject to Remediation, Deactivation or Decertification.

---

\(^1\) See New Certification process
**Remediation**

A Medical Director may require the Paramedic to receive Remediation. The customized plan in the Remediation shall identify the concern, the remedial action to be followed, and the objectives to be achieved. The plan shall include a specific timeframe in which the Paramedic must successfully complete the Remediation. The RBHP shall develop the plan, in consultation with the Employer as necessary, as soon as possible. Once developed, the RBHP shall provide the written plan to the Paramedic and Employer. Any changes to the plan by the RBHP shall be communicated to the Paramedic and Employer immediately and the updated written plan shall be provided as soon as possible. The Medical Director shall notify the Paramedic and Employer in writing within three (3) Business Days of the successful completion of the Remediation.

**Deactivation**

A Medical Director may deactivate a Paramedic’s Certification for which the Paramedic has received Authorization.

Deactivation may occur as a result of:

1. a Patient Care Concern;
2. failure to respond to the RBHP’s requests for feedback or interviews regarding a Critical Omission or Commission, Major Omission or Commission or Minor Omission or Commission within a reasonable period of time as specified by the RBHP;
3. failure to successfully complete Remediation;
4. misconduct related to Certification (e.g. falsification of documentation, failure to disclose previous Deactivations and Decertifications, including practice in other jurisdictions);
5. repeated Deactivations in similar clinical areas; or
6. failure to meet the requirements for maintenance of Certification.

The Medical Director shall immediately notify the Paramedic, Employer, the Senior Field Manager and all other RBHPs of a Deactivation. The Medical Director shall provide a brief written reason for the Deactivation to the Paramedic, Employer, the Senior Field Manager and all other RBHPs as soon as possible.

Following a Deactivation, the Medical Director shall determine whether the requirements for Remediation or the requirements for maintenance of Certification have been met, as the case may be, at which time the Medical Director shall either proceed with Reactivation or Decertification. The Remediation and Reactivation process shall be completed as soon as possible; however it shall not exceed ninety (90) consecutive days in length. Where the Medical Director has proceeded with Reactivation, the Medical Director shall immediately notify the Paramedic, Employer, the Senior Field Manager, and all other RBHPs of the Reactivation.
**Decertification**

A Medical Director shall revoke a Paramedic’s Certification where that person is no longer employed or retained as a volunteer by an Employer and that person shall be deemed to have undergone Decertification and the PPRC process does not apply. In all other circumstances, a Medical Director shall not proceed with a Decertification unless: (i) a PPRC has been convened and has provided its written recommendations to the Medical Director and the Paramedic; or (ii) the Paramedic has waived the PPRC process in writing.

The Medical Director shall immediately notify the Paramedic, Employer, the Senior Field Manager and all other RBHPs of his or her decision to either proceed with Reactivation or Decertification of the Paramedic. Where the Medical Director proceeds with Decertification, he or she shall provide a written explanation to the Paramedic, outlining the reasons for Decertification. The Medical Director shall provide a brief written explanation confirming the reason for the Decertification to the Employer, the Senior Field Manager and all other RBHPs as soon as possible.

**NEW CERTIFICATION**

The following requirements apply with respect to Paramedics who are seeking Certification from an RBHP and who are not currently certified at that level by another RBHP, including Paramedics who have been previously certified in Ontario.

1. The Paramedic shall be employed or retained by an Employer.
2. The Paramedic shall complete a form provided by the RBHP that includes the following:
   a. a list of all RBHPs or other certifying bodies under which the Paramedic has previously received Certification within the ten (10) year period immediately preceding the application;
   b. a declaration of the dates of all previous Deactivations and/or Decertifications that have previously occurred at all other RBHPs or other certifying bodies within the ten (10) year period immediately preceding the application; and
   c. written permission for the prospective RBHP to obtain information in writing from other employers, other physicians, other programs, etc. regarding the Paramedic’s previous practice.
3. The Paramedic shall successfully complete an evaluation by the RBHP and any orientation and training required by the RBHP. The evaluation may include:
   a. an assessment of knowledge and skills;
   b. a scenario evaluation; and
   c. an oral interview or clinical evaluation with the Medical Director or designate.

Upon meeting the above requirements, for new Certification, the Medical Director shall certify the Paramedic and require a condition of Consolidation on the Paramedic’s Certification.

---

2 Or a declaration of dates when certification was denied, revoked, suspended or under review as other certifying bodies may not use the terms Deactivation and Decertification
**CROSS CERTIFICATION**

The following requirements apply with respect to Paramedics who are already certified and who are seeking Certification by a Medical Director in another RBHP.

1. The Paramedic shall be employed or retained by an Employer within the specified catchment area.
2. The Paramedic shall complete a form provided by the RBHP that includes the following:
   a. a list of all RBHPs under which the Paramedic has received Certification within the ten (10) year period immediately preceding the application;
   b. a declaration of the dates of all previous Deactivations and/or Decertifications that have occurred within the ten (10) year period immediately preceding the application;
   c. status of all current Certifications from all RBHPs; and
   d. written permission for the prospective RBHP to obtain information in writing from other physicians, other programs, etc. regarding the Paramedic’s previous practice.
3. The Paramedic shall successfully complete an evaluation by the RBHP and any orientation and training required by the RBHP. The evaluation may include:
   a. an assessment of knowledge and skills;
   b. scenario evaluation; and
   c. oral interview or clinical evaluation with the Medical Director or designate.

Upon meeting the above requirements for Cross Certification, the Medical Director shall certify the Paramedic.

**MAINTENANCE OF CERTIFICATION**

The following requirements apply with respect to Paramedics regarding the maintenance of Certification.

1. The Paramedic shall demonstrate competency in the performance of Controlled Acts and other advanced medical procedures, compliance with the ALS PCS, and the provision of patient care at the Paramedic’s level of Certification. Competency and compliance shall be determined by the Medical Director and may include chart audits, field evaluations, and RBHP patch communication review.
2. The Paramedic shall not have an absence from providing patient care that exceeds ninety (90) consecutive days.
3. The Paramedic shall either,
   a. provide patient care to a minimum of ten (10) patients per year whose care requires assessment and management at the Paramedic’s level of Certification, or
   b. where a Paramedic is unable to assess and manage the minimum of ten (10) patients per year, demonstrate alternate experience, as approved by the Medical Director, that may involve one or more of the following:
      i. other patient care activities;
      ii. additional CME;
      iii. simulated patient encounters; and
      iv. clinical placements.
4. The Paramedic shall complete at least one evaluation per year at the appropriate level of Certification, which may include: an assessment of knowledge and evaluation of skills; scenarios; and on-line learning and evaluation.

5. The Paramedic shall complete a minimum of CME hours per year as follows: eight (8) hours for PCPs, twelve (12) hours for PCP Flight, twenty-four (24) hours for ACPs, and seventy-two (72) hours for ACP Flight and CCP. CME hours include hours completed as part of an evaluation required by paragraph 4.

Upon meeting the above requirements for maintenance of Certification, the Medical Director shall certify the Paramedic.

PARAMEDIC PRACTICE REVIEW COMMITTEE (PPRC)

The PPRC is convened by another RBHP through the OBHG Executive Chair to perform an independent, external advisory role, providing information and expert opinion to the affected Medical Director on issues related to Paramedic practice when a Medical Director is considering Decertification of a Paramedic following Deactivation. When the RBHP is engaged for the purposes of a PPRC process the RBHP is termed the "host RBHP". The parties to the PPRC process are the affected Medical Director and the Paramedic who is subject of the consideration of Decertification.

Membership

The members of the PPRC shall be:

- the host RBHP Manager/Director, who will act as Chair;
- host Medical Director; and
- two (2) Peer Paramedics.

Selection of Peer Paramedics: One (1) peer Paramedic shall be selected by the host RBHP and one (1) peer Paramedic by the affected Paramedic from a pre-identified group of eligible Paramedics. All members of this group shall:

- hold Certification from the host RBHP for the preceding twelve (12) months at the same level or higher as the Paramedic who is subject of the consideration of Decertification; and
- not have any operational relationship or personal relationship with the affected RBHP, Medical Director, or the Paramedic;

Confidentiality: All members of the PPRC shall keep confidential all information obtained during the PPRC process.

---

3 With respect to an ACP whose Certification has been for a period of less than a year and who has completed a minimum of eight (8) hours of CME, the Medical Director shall proportionally adjust the remaining required CME hours.


**Recommendations**

The PPRC shall provide written recommendations, including supporting rationale, to the Medical Director regarding the consideration to decertify a Paramedic. The recommendation of the PPRC shall be made by consensus. The recommendation rendered by the PPRC is not subject to appeal or other challenge, and is not binding on the affected Medical Director. The affected Medical Director is responsible for making the final decision with respect to the Decertification of the affected Paramedic.

**PPRC Process**

1. The affected Medical Director shall notify the OBHG Executive Chair that a PPRC is required regarding a consideration to proceed with the Decertification of a Paramedic.
2. If the OBHG Executive Chair is employed by the affected RBHP, he/she shall send the request to the OBHG Executive Vice Chair. (All subsequent references to the “OBHG Executive Chair” shall be references to the OBHG Executive Vice Chair, as applicable.)
3. The OBHG Executive Chair shall ensure that the PPRC adheres to all established times lines in the process by communicating directly with the PPRC Chair.
4. The OBHG Executive Chair shall select an appropriate host RBHP.
5. The OBHG Executive Chair shall provide notice to the affected Medical Director and Paramedic, in a format set out in Appendix A, that a PPRC has been convened to review the case.
6. The affected Medical Director and Paramedic shall provide any written submissions to the OBHG Executive Chair within fifteen (15) Business Days of receiving notice that a PPRC has been convened.
7. Submissions shall be sent via courier requiring signature of receipt, registered mail, fax (with confirmation) or email (with confirmation).
8. The OBHG Executive Chair shall provide a copy of each party’s submission to the other party within five (5) Business Days.
9. Both parties shall have the opportunity to respond to the original submissions within fifteen (15) Business Days of their receipt.
10. The OBHG Executive Chair shall provide a copy of all submissions to the affected Paramedic, Medical Director and four (4) copies to the PPRC Chair.
11. The PPRC Chair shall provide copies of the submissions to the other members of the PPRC.
12. The PPRC shall not begin its review until receipt of all submissions.
13. If clarification of an issue or information regarding applicable standards or legislation is required, the PPRC Chair shall request the clarification or information in writing from the relevant party. The response to the request shall be provided to the PPRC Chair and the other party in writing, within ten (10) Business Days of the request.
14. The PPRC Chair shall provide a copy of the response to OBHG Executive Chair.
15. The PPRC shall review the submissions and any responses within fifteen (15) Business Days from receipt of the full submission. If an extension is required the request will be made to the OBHG Executive Chair. The PPRC will render a written recommendation containing the supporting rationale, within ten (10) Business Days of the final review meeting and submit it to the OBHG Executive Chair.
16. The OBHG Executive Chair shall send a copy of the final recommendation to both parties.
APPENDIX A

PARAMEDIC PRACTICE REVIEW COMMITTEE LETTER

<<Date>>

A Paramedic Practice Review Committee (PPRC) has been convened to review <<brief details of case/incident>>.

The PPRC is convened by another RBHP through the OBHG Executive Chair to perform an independent, external advisory role, providing information and expert opinion to the affected Medical Director on issues related to Paramedic practice when a Medical Director is considering Decertification of a Paramedic following Deactivation. When the RBHP is engaged for the purposes of a PPRC process the RBHP is termed the "host RBHP". The affected Medical Director shall not proceed with Decertification unless a PPRC has been convened and has provided its written recommendations to the affected Medical Director and the Paramedic.

Recommendations
The PPRC shall provide written recommendations, including supporting rationale, to the Medical Director regarding the consideration to decertify a Paramedic. The recommendation of the PPRC shall be made by consensus. The recommendation rendered by the PPRC is not subject to appeal or other challenge, and is not binding on the affected Medical Director. The affected Medical Director is responsible for making the final decision with respect to the Decertification of the affected Paramedic.

Membership
<<Medical Director>>  <<Regional Base Hospital Program Manager/Director>>
<<Peer Paramedic>>  <<Peer Paramedic>>
Process:

- The affected Medical Director shall notify the OBHG Executive Chair that a PPRC is required regarding a consideration to proceed with the Decertification of a Paramedic.
- The OBHG Executive Chair shall select an appropriate host RBHP and provide notice to both parties that a PPRC has been convened to review the case.
- Both parties shall provide any written submissions to the OBHG Executive Chair within fifteen (15) Business Days of receiving notice that a PPRC has been convened.
- The OBHG Executive Chair shall provide a copy of each party’s submission to the other party within five (5) Business Days and both parties shall have the opportunity to respond to the original submissions within fifteen (15) Business Days of their receipt.
- The OBHG Executive Chair shall provide a copy of all submissions to both parties and four (4) copies to the PPRC Chair to distribute to the other members of the PPRC. The PPRC shall begin its review once all submissions are received.
- If clarification of an issue or information regarding applicable standards or legislation is required, the PPRC Chair shall request the clarification or information in writing from the relevant party. The response to the request shall be provided to the PPRC Chair and the other party in writing, within ten (10) Business Days of the request.
- The PPRC shall review the submissions and any responses within fifteen (15) Business Days from receipt of the full submission. If an extension is required the request will be made to the OBHG Executive Chair.
- The PPRC will render a written recommendation containing the supporting rationale, within ten (10) Business Days of the final review meeting and submit it to the OBHG Executive Chair.
- The OBHG Executive Chair shall send a copy of the final recommendation to both parties.